Gut microbiota dysbiosis in HCC.
\r\n\tThe most phenomena of colloids in the surrounding ecosystem appear in the blue color of the sky, which due to the scattering of light by colloidal particles in the air, and this phenomenon is named Tyndall effect. Also, seawater seems blue due to scattering of light by the colloidal particle present in seawater. In our body, blood is a colloidal solution. Some examples in our daily life include milk, cream, gelatin, colored glass, butter, jelly, and river mud. Colloids are useful for human health, commercial, and industrial use. Colloids and colloidal systems are essential and play a significant role in our life. Important applications of colloids are in medicines, sewage disposal, purification of water, cleansing action of soap, the formation of the delta, industry, mining, smoke precipitation, photography, electroplating, artificial rain, agriculture, the rubber industry, and others.
\r\n\r\n\tThis book aims to gather recent researches by outstanding experts in the field of colloids (chemistry, physics, biology, medicine, nanotechnology, pharmacology, and others), which include colloid synthesis, modification, and application.
",isbn:"978-1-83962-979-2",printIsbn:"978-1-83962-969-3",pdfIsbn:"978-1-83962-980-8",doi:null,price:0,priceEur:0,priceUsd:0,slug:null,numberOfPages:0,isOpenForSubmission:!1,hash:"55025219ea1a8b915ec8aa4b9f497a8d",bookSignature:"Prof. Mohamed Nageeb Rashed",publishedDate:null,coverURL:"https://cdn.intechopen.com/books/images_new/10505.jpg",keywords:"Colloids, Biotechnology, Industry, Colloidal Systems, Human Health, Nutrition, Intravenous Therapy, Pharmacology, Drugs, Wastewater Treatment, Nanocolloids, Green Nanocolloids",numberOfDownloads:410,numberOfWosCitations:0,numberOfCrossrefCitations:0,numberOfDimensionsCitations:0,numberOfTotalCitations:0,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"June 30th 2020",dateEndSecondStepPublish:"July 21st 2020",dateEndThirdStepPublish:"September 19th 2020",dateEndFourthStepPublish:"December 8th 2020",dateEndFifthStepPublish:"February 6th 2021",remainingDaysToSecondStep:"6 months",secondStepPassed:!0,currentStepOfPublishingProcess:5,editedByType:null,kuFlag:!1,biosketch:"Professor of analytical and environmental chemistry, member of several national and international societies, and winner of the Egyptian State Award for Environmental Researches.",coeditorOneBiosketch:null,coeditorTwoBiosketch:null,coeditorThreeBiosketch:null,coeditorFourBiosketch:null,coeditorFiveBiosketch:null,editors:[{id:"63465",title:"Prof.",name:"Mohamed Nageeb",middleName:null,surname:"Rashed",slug:"mohamed-nageeb-rashed",fullName:"Mohamed Nageeb Rashed",profilePictureURL:"https://mts.intechopen.com/storage/users/63465/images/system/63465.gif",biography:"Prof. Mohamed Nageeb Rashed is a professor of analytical and environmental chemistry, a previous vice-dean for environmental affairs, Faculty of Science, Aswan University, Egypt. In 1989 he received his Ph.D. in analytical environmental chemistry from Assiut University, Egypt. His research interest has been analytical and environmental chemistry with special emphasis on soil and water pollution monitoring, control and treatment; bioindicators for water pollution monitoring; wastewater impact; advanced oxidation treatment; photocatalysis, nanocatalyst, nanocomposite and adsorption techniques in water and wastewater treatment. Prof. Rashed supervised several M.Sc. and Ph.D. thesis in the field of pollution, analytical and environmental chemistry. He participated as an invited speaker in 30 international conferences worldwide. Prof.Rashed acts as editor-in-chief and an editorial board member in several international journals (30) in the fields of chemistry and environment. His society membership includes several national and international societies. Prof.Rashed was awarded the Egyptian State Award for Environmental Researches for the year 2001, and enrolled among Top 2% Scientists Around the World from Stanford University, USA, 2020.",institutionString:"Aswan University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"2",totalChapterViews:"0",totalEditedBooks:"3",institution:{name:"Aswan University",institutionURL:null,country:{name:"Egypt"}}}],coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"8",title:"Chemistry",slug:"chemistry"}],chapters:[{id:"74126",title:"A Simple and “Green” Technique to Synthesize Metal Nanocolloids by Ultrashort Light Pulses",slug:"a-simple-and-green-technique-to-synthesize-metal-nanocolloids-by-ultrashort-light-pulses",totalDownloads:53,totalCrossrefCites:0,authors:[null]},{id:"73791",title:"Gemini Imidazolinium Surfactants: A Versatile Class of Molecules",slug:"gemini-imidazolinium-surfactants-a-versatile-class-of-molecules",totalDownloads:25,totalCrossrefCites:0,authors:[null]},{id:"74505",title:"Optimization of Biogenic Synthesis of Colloidal Metal Nanoparticles",slug:"optimization-of-biogenic-synthesis-of-colloidal-metal-nanoparticles",totalDownloads:97,totalCrossrefCites:0,authors:[null]},{id:"74609",title:"Magnetic Iron Oxide Colloids for Environmental Applications",slug:"magnetic-iron-oxide-colloids-for-environmental-applications",totalDownloads:54,totalCrossrefCites:0,authors:[null]},{id:"73859",title:"Colloidal Stability of Cellulose Suspensions",slug:"colloidal-stability-of-cellulose-suspensions",totalDownloads:55,totalCrossrefCites:0,authors:[null]},{id:"73574",title:"Structure and Dynamics of Aqueous Dispersions",slug:"structure-and-dynamics-of-aqueous-dispersions",totalDownloads:101,totalCrossrefCites:0,authors:[null]},{id:"72963",title:"Aerogels Utilization in Electrochemical Capacitors",slug:"aerogels-utilization-in-electrochemical-capacitors",totalDownloads:32,totalCrossrefCites:0,authors:[{id:"271773",title:"Dr.",name:"Ranganatha",surname:"S",slug:"ranganatha-s",fullName:"Ranganatha S"}]}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},personalPublishingAssistant:{id:"205697",firstName:"Kristina",lastName:"Kardum Cvitan",middleName:null,title:"Ms.",imageUrl:"https://mts.intechopen.com/storage/users/205697/images/5186_n.jpg",email:"kristina.k@intechopen.com",biography:"As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact."}},relatedBooks:[{type:"book",id:"3426",title:"Organic Pollutants",subtitle:"Monitoring, Risk and Treatment",isOpenForSubmission:!1,hash:"4dafb52ed4f5e21f079ab4b2f6825e78",slug:"organic-pollutants-monitoring-risk-and-treatment",bookSignature:"M. Nageeb Rashed",coverURL:"https://cdn.intechopen.com/books/images_new/3426.jpg",editedByType:"Edited by",editors:[{id:"63465",title:"Prof.",name:"Mohamed Nageeb",surname:"Rashed",slug:"mohamed-nageeb-rashed",fullName:"Mohamed Nageeb Rashed"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5282",title:"Lake Sciences and Climate Change",subtitle:null,isOpenForSubmission:!1,hash:"34ba6ce6df0e6f5c99263d7d80907861",slug:"lake-sciences-and-climate-change",bookSignature:"M.Nageeb Rashed",coverURL:"https://cdn.intechopen.com/books/images_new/5282.jpg",editedByType:"Edited by",editors:[{id:"63465",title:"Prof.",name:"Mohamed Nageeb",surname:"Rashed",slug:"mohamed-nageeb-rashed",fullName:"Mohamed Nageeb Rashed"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6499",title:"Zeolites and Their Applications",subtitle:null,isOpenForSubmission:!1,hash:"79c24d88452b8f5f51df9fcfb2116920",slug:"zeolites-and-their-applications",bookSignature:"M.Nageeb Rashed and P.N. Palanisamy",coverURL:"https://cdn.intechopen.com/books/images_new/6499.jpg",editedByType:"Edited by",editors:[{id:"63465",title:"Prof.",name:"Mohamed Nageeb",surname:"Rashed",slug:"mohamed-nageeb-rashed",fullName:"Mohamed Nageeb Rashed"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1591",title:"Infrared Spectroscopy",subtitle:"Materials Science, Engineering and Technology",isOpenForSubmission:!1,hash:"99b4b7b71a8caeb693ed762b40b017f4",slug:"infrared-spectroscopy-materials-science-engineering-and-technology",bookSignature:"Theophile Theophanides",coverURL:"https://cdn.intechopen.com/books/images_new/1591.jpg",editedByType:"Edited by",editors:[{id:"37194",title:"Dr.",name:"Theophanides",surname:"Theophile",slug:"theophanides-theophile",fullName:"Theophanides Theophile"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3092",title:"Anopheles mosquitoes",subtitle:"New insights into malaria vectors",isOpenForSubmission:!1,hash:"c9e622485316d5e296288bf24d2b0d64",slug:"anopheles-mosquitoes-new-insights-into-malaria-vectors",bookSignature:"Sylvie Manguin",coverURL:"https://cdn.intechopen.com/books/images_new/3092.jpg",editedByType:"Edited by",editors:[{id:"50017",title:"Prof.",name:"Sylvie",surname:"Manguin",slug:"sylvie-manguin",fullName:"Sylvie Manguin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3161",title:"Frontiers in Guided Wave Optics and Optoelectronics",subtitle:null,isOpenForSubmission:!1,hash:"deb44e9c99f82bbce1083abea743146c",slug:"frontiers-in-guided-wave-optics-and-optoelectronics",bookSignature:"Bishnu Pal",coverURL:"https://cdn.intechopen.com/books/images_new/3161.jpg",editedByType:"Edited by",editors:[{id:"4782",title:"Prof.",name:"Bishnu",surname:"Pal",slug:"bishnu-pal",fullName:"Bishnu Pal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"72",title:"Ionic Liquids",subtitle:"Theory, Properties, New Approaches",isOpenForSubmission:!1,hash:"d94ffa3cfa10505e3b1d676d46fcd3f5",slug:"ionic-liquids-theory-properties-new-approaches",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/72.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1373",title:"Ionic Liquids",subtitle:"Applications and Perspectives",isOpenForSubmission:!1,hash:"5e9ae5ae9167cde4b344e499a792c41c",slug:"ionic-liquids-applications-and-perspectives",bookSignature:"Alexander Kokorin",coverURL:"https://cdn.intechopen.com/books/images_new/1373.jpg",editedByType:"Edited by",editors:[{id:"19816",title:"Prof.",name:"Alexander",surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"57",title:"Physics and Applications of Graphene",subtitle:"Experiments",isOpenForSubmission:!1,hash:"0e6622a71cf4f02f45bfdd5691e1189a",slug:"physics-and-applications-of-graphene-experiments",bookSignature:"Sergey Mikhailov",coverURL:"https://cdn.intechopen.com/books/images_new/57.jpg",editedByType:"Edited by",editors:[{id:"16042",title:"Dr.",name:"Sergey",surname:"Mikhailov",slug:"sergey-mikhailov",fullName:"Sergey Mikhailov"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"371",title:"Abiotic Stress in Plants",subtitle:"Mechanisms and Adaptations",isOpenForSubmission:!1,hash:"588466f487e307619849d72389178a74",slug:"abiotic-stress-in-plants-mechanisms-and-adaptations",bookSignature:"Arun Shanker and B. Venkateswarlu",coverURL:"https://cdn.intechopen.com/books/images_new/371.jpg",editedByType:"Edited by",editors:[{id:"58592",title:"Dr.",name:"Arun",surname:"Shanker",slug:"arun-shanker",fullName:"Arun Shanker"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},chapter:{item:{type:"chapter",id:"23137",title:"Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus",doi:"10.5772/20616",slug:"role-of-incretin-incretin-analogues-and-dipeptidyl-peptidase-4-inhibitors-in-the-pathogenesis-and-tr",body:null,keywords:null,chapterPDFUrl:"https://cdn.intechopen.com/pdfs/23137.pdf",chapterXML:null,downloadPdfUrl:"/chapter/pdf-download/23137",previewPdfUrl:"/chapter/pdf-preview/23137",totalDownloads:1518,totalViews:121,totalCrossrefCites:0,totalDimensionsCites:0,hasAltmetrics:0,dateSubmitted:"November 9th 2010",dateReviewed:"April 7th 2011",datePrePublished:null,datePublished:"November 9th 2011",dateFinished:null,readingETA:"0",abstract:null,reviewType:"peer-reviewed",bibtexUrl:"/chapter/bibtex/23137",risUrl:"/chapter/ris/23137",book:{slug:"diabetes-damages-and-treatments"},signatures:"Athanasia K. Papazafiropoulou, Marina S. Kardara and Stavros I. Pappas",authors:[{id:"39771",title:"Dr.",name:"Athanasia",middleName:null,surname:"Papazafiropoulou",fullName:"Athanasia Papazafiropoulou",slug:"athanasia-papazafiropoulou",email:"pathan@ath.forthnet.gr",position:null,institution:null},{id:"47512",title:"Dr.",name:"Marina",middleName:null,surname:"Kardara",fullName:"Marina Kardara",slug:"marina-kardara",email:"mkardara@yahoo.gr",position:null,institution:null},{id:"47513",title:"Dr.",name:"Stavros",middleName:null,surname:"Pappas",fullName:"Stavros Pappas",slug:"stavros-pappas",email:"s.pappas@nikaia-hosp.gr",position:null,institution:{name:"General Hospital Nice Piraeus Saint Panteleimon",institutionURL:null,country:{name:"Greece"}}}],sections:null,chapterReferences:null,footnotes:null,contributors:null,corrections:null},book:{id:"1357",title:"Diabetes",subtitle:"Damages and Treatments",fullTitle:"Diabetes - Damages and Treatments",slug:"diabetes-damages-and-treatments",publishedDate:"November 9th 2011",bookSignature:"Everlon Cid Rigobelo",coverURL:"https://cdn.intechopen.com/books/images_new/1357.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"39553",title:"Prof.",name:"Everlon",middleName:"Cid",surname:"Rigobelo",slug:"everlon-rigobelo",fullName:"Everlon Rigobelo"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"23123",title:"Management Approach to Hypoglycemia",slug:"management-approach-to-hypoglycemia",totalDownloads:11963,totalCrossrefCites:1,signatures:"Miriam Ciljakova, Milos Jesenak, Miroslava Brndiarova and Peter Banovcin",authors:[{id:"59501",title:"Dr.",name:"Miroslava",middleName:null,surname:"Brndiarová",fullName:"Miroslava Brndiarová",slug:"miroslava-brndiarova"},{id:"59696",title:"Prof.",name:"Miriam",middleName:null,surname:"Ciljakova",fullName:"Miriam Ciljakova",slug:"miriam-ciljakova"}]},{id:"23124",title:"Hypoglycemia in Children Attending the Critical Care Medicine in Developing Countries",slug:"hypoglycemia-in-children-attending-the-critical-care-medicine-in-developing-countries",totalDownloads:6402,totalCrossrefCites:0,signatures:"Mohammod Jobayer Chisti, Tahmeed Ahmed, Hasan Ashraf, Abu Syeed Golam Faruque, Sayeeda Huq and Md Iqbal Hossain",authors:[{id:"12710",title:"Dr.",name:"Hasan",middleName:null,surname:"Ashraf",fullName:"Hasan Ashraf",slug:"hasan-ashraf"},{id:"51946",title:"Dr.",name:"Mohammod Jobayer",middleName:null,surname:"Chisti",fullName:"Mohammod Jobayer Chisti",slug:"mohammod-jobayer-chisti"},{id:"61375",title:"Prof.",name:"Tahmeed",middleName:null,surname:"Ahmed",fullName:"Tahmeed Ahmed",slug:"tahmeed-ahmed"},{id:"61376",title:"Prof.",name:"Sayeeda",middleName:null,surname:"Huq",fullName:"Sayeeda Huq",slug:"sayeeda-huq"},{id:"61377",title:"Prof.",name:"Md Iqbal",middleName:null,surname:"Hossain",fullName:"Md Iqbal Hossain",slug:"md-iqbal-hossain"},{id:"92349",title:"Dr.",name:"Abu Syeed Golam",middleName:null,surname:"Faruque",fullName:"Abu Syeed Golam Faruque",slug:"abu-syeed-golam-faruque"}]},{id:"23125",title:"Brittle Diabetes: A Contemporary Review of the Myth and Its Realization",slug:"brittle-diabetes-a-contemporary-review-of-the-myth-and-its-realization",totalDownloads:9594,totalCrossrefCites:0,signatures:"Christina Voulgari and Nicholas Tentolouris",authors:[{id:"52641",title:"Dr.",name:"Christina",middleName:null,surname:"Voulgari",fullName:"Christina Voulgari",slug:"christina-voulgari"},{id:"55077",title:"Prof.",name:"Nicholas",middleName:null,surname:"Tentolouris",fullName:"Nicholas Tentolouris",slug:"nicholas-tentolouris"}]},{id:"23126",title:"Hypoglycemia in Critically Ill Patients",slug:"hypoglycemia-in-critically-ill-patients",totalDownloads:4278,totalCrossrefCites:0,signatures:"Cornelia Hoedemaekers and Johannes van der Hoeven",authors:[{id:"57055",title:"Dr.",name:"Cornelia",middleName:null,surname:"Hoedemaekers",fullName:"Cornelia Hoedemaekers",slug:"cornelia-hoedemaekers"},{id:"57082",title:"Prof.",name:"Johannnes",middleName:null,surname:"Van Der Hoeven",fullName:"Johannnes Van Der Hoeven",slug:"johannnes-van-der-hoeven"}]},{id:"23127",title:"Inflammation and Hypoglycemia: The Lipid Connection",slug:"inflammation-and-hypoglycemia-the-lipid-connection",totalDownloads:5088,totalCrossrefCites:0,signatures:"Oren Tirosh",authors:[{id:"55675",title:"Dr.",name:"Oren",middleName:null,surname:"Tirosh",fullName:"Oren Tirosh",slug:"oren-tirosh"}]},{id:"23128",title:"Postprandial Hypoglycemia",slug:"postprandial-hypoglycemia",totalDownloads:8826,totalCrossrefCites:0,signatures:"Mubeen Khan and Udaya M. Kabadi",authors:[{id:"57203",title:"Dr.",name:"Udaya",middleName:null,surname:"Kabadi",fullName:"Udaya Kabadi",slug:"udaya-kabadi"}]},{id:"23129",title:"The Role of the Pituitary-Growth Hormone-IGF Axis in Glucose Homeostasis",slug:"the-role-of-the-pituitary-growth-hormone-igf-axis-in-glucose-homeostasis",totalDownloads:2762,totalCrossrefCites:0,signatures:"Stephen F. Kemp",authors:[{id:"40146",title:"Dr.",name:"Stephen",middleName:null,surname:"Kemp",fullName:"Stephen Kemp",slug:"stephen-kemp"}]},{id:"23130",title:"Molecular Mechanism Underlying the Intra-Islet Regulation of Glucagon Secretion",slug:"molecular-mechanism-underlying-the-intra-islet-regulation-of-glucagon-secretion",totalDownloads:2794,totalCrossrefCites:0,signatures:"Dan Kawamori and Rohit N. Kulkarni",authors:[{id:"59544",title:"Dr.",name:"Dan",middleName:null,surname:"Kawamori",fullName:"Dan Kawamori",slug:"dan-kawamori"},{id:"59547",title:"Dr.",name:"Rohit",middleName:null,surname:"Kulkarni",fullName:"Rohit Kulkarni",slug:"rohit-kulkarni"}]},{id:"23131",title:"Insulin Therapy and Hypoglycemia - Present and Future",slug:"insulin-therapy-and-hypoglycemia-present-and-future",totalDownloads:1871,totalCrossrefCites:0,signatures:"Simona Cernea, Ron Nagar, Gabriel Bitton and Itamar Raz",authors:[{id:"59882",title:"Prof.",name:"Itamar",middleName:null,surname:"Raz",fullName:"Itamar Raz",slug:"itamar-raz"},{id:"119649",title:"Dr.",name:"Simona",middleName:null,surname:"Cernea",fullName:"Simona Cernea",slug:"simona-cernea"},{id:"119650",title:"Dr.",name:"Ron",middleName:null,surname:"Nagar",fullName:"Ron Nagar",slug:"ron-nagar"},{id:"119651",title:"Dr.",name:"Gabriel",middleName:null,surname:"Bitton",fullName:"Gabriel Bitton",slug:"gabriel-bitton"}]},{id:"23132",title:"Prevention of Hospital Hypoglycemia by Algorithm Design: A Programming Pathway for Electronic Order Entry",slug:"prevention-of-hospital-hypoglycemia-by-algorithm-design-a-programming-pathway-for-electronic-order-e",totalDownloads:5090,totalCrossrefCites:0,signatures:"Susan S. Braithwaite, Lisa Clark, Lydia Dacenko-Grawe, Radha Devi, Josefina Diaz, Mehran Javadi and Harley Salinas",authors:[{id:"53252",title:"Dr.",name:"Susan S.",middleName:"Shapiro",surname:"Braithwaite",fullName:"Susan S. Braithwaite",slug:"susan-s.-braithwaite"},{id:"88903",title:"BSc.",name:"Lydia",middleName:null,surname:"Dacenko-Grawe",fullName:"Lydia Dacenko-Grawe",slug:"lydia-dacenko-grawe"},{id:"88904",title:"Ms.",name:"Lisa",middleName:null,surname:"Clark",fullName:"Lisa Clark",slug:"lisa-clark"},{id:"89303",title:"BSc.",name:"Mehran",middleName:null,surname:"Javadi",fullName:"Mehran Javadi",slug:"mehran-javadi"},{id:"89320",title:"Dr.",name:"Radha",middleName:null,surname:"Devi",fullName:"Radha Devi",slug:"radha-devi"},{id:"90310",title:"Dr.",name:"Josefina",middleName:null,surname:"Diaz",fullName:"Josefina Diaz",slug:"josefina-diaz"},{id:"90311",title:"Mr.",name:"Harley",middleName:null,surname:"Salinas",fullName:"Harley Salinas",slug:"harley-salinas"}]},{id:"23133",title:"Hypoglycemia Prevention in Closed-Loop Artificial Pancreas for Patients with Type 1 Diabetes",slug:"hypoglycemia-prevention-in-closed-loop-artificial-pancreas-for-patients-with-type-1-diabetes",totalDownloads:2086,totalCrossrefCites:2,signatures:"Amjad Abu-Rmileh and Winston Garcia-Gabin",authors:[{id:"48551",title:"Dr.",name:"Amjad",middleName:"Hisham",surname:"Abu-Rmileh",fullName:"Amjad Abu-Rmileh",slug:"amjad-abu-rmileh"},{id:"56631",title:"Dr.",name:"Winston",middleName:null,surname:"Garcia-Gabin",fullName:"Winston Garcia-Gabin",slug:"winston-garcia-gabin"}]},{id:"23134",title:"Glucose Homeostasis – Mechanism and Defects",slug:"glucose-homeostasis-mechanism-and-defects",totalDownloads:29551,totalCrossrefCites:2,signatures:"Leszek Szablewski",authors:[{id:"49739",title:"Dr.",name:"Leszek",middleName:null,surname:"Szablewski",fullName:"Leszek Szablewski",slug:"leszek-szablewski"}]},{id:"23135",title:"Neurologic Manifestations of Hypoglycemia",slug:"neurologic-manifestations-of-hypoglycemia",totalDownloads:6660,totalCrossrefCites:0,signatures:"William P. Neil and Thomas M. Hemmen",authors:[{id:"46773",title:"Dr.",name:"Thomas",middleName:null,surname:"Hemmen",fullName:"Thomas Hemmen",slug:"thomas-hemmen"},{id:"57448",title:"Dr.",name:"William",middleName:null,surname:"Neil",fullName:"William Neil",slug:"william-neil"}]},{id:"23136",title:"Hypoglycemia Associated with Type B Insulin Resistance",slug:"hypoglycemia-associated-with-type-b-insulin-resistance",totalDownloads:2863,totalCrossrefCites:0,signatures:"Hiroyuki Tamemoto, Shin-ichi Tominaga Hideo Toyoshima, San-e’ Ishikawa and Masanobu Kawakami",authors:[{id:"56898",title:"Dr.",name:"Hiroyuki",middleName:null,surname:"Tamemoto",fullName:"Hiroyuki Tamemoto",slug:"hiroyuki-tamemoto"},{id:"62348",title:"Prof.",name:"Masanobu",middleName:null,surname:"Kawakami",fullName:"Masanobu Kawakami",slug:"masanobu-kawakami"},{id:"108207",title:"Prof.",name:"Shin-Ichi",middleName:null,surname:"Tominaga",fullName:"Shin-Ichi Tominaga",slug:"shin-ichi-tominaga"},{id:"108209",title:"Prof.",name:"San-E",middleName:null,surname:"Ishikawa",fullName:"San-E Ishikawa",slug:"san-e-ishikawa"}]},{id:"23137",title:"Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus",slug:"role-of-incretin-incretin-analogues-and-dipeptidyl-peptidase-4-inhibitors-in-the-pathogenesis-and-tr",totalDownloads:1518,totalCrossrefCites:0,signatures:"Athanasia K. Papazafiropoulou, Marina S. Kardara and Stavros I. Pappas",authors:[{id:"39771",title:"Dr.",name:"Athanasia",middleName:null,surname:"Papazafiropoulou",fullName:"Athanasia Papazafiropoulou",slug:"athanasia-papazafiropoulou"},{id:"47512",title:"Dr.",name:"Marina",middleName:null,surname:"Kardara",fullName:"Marina Kardara",slug:"marina-kardara"},{id:"47513",title:"Dr.",name:"Stavros",middleName:null,surname:"Pappas",fullName:"Stavros Pappas",slug:"stavros-pappas"}]},{id:"23138",title:"Zinc Translocation Causes Hypoglycemia-Induced Neuron Death",slug:"zinc-translocation-causes-hypoglycemia-induced-neuron-death",totalDownloads:1718,totalCrossrefCites:0,signatures:"Sang Won Suh",authors:[{id:"40070",title:"Dr.",name:"Sang Won",middleName:null,surname:"Suh",fullName:"Sang Won Suh",slug:"sang-won-suh"}]},{id:"23139",title:"Congenital Hyperinsulinism",slug:"congenital-hyperinsulinism",totalDownloads:2047,totalCrossrefCites:0,signatures:"Xinhua Xiao and Si Chen",authors:[{id:"45776",title:"Prof.",name:"Xinhua",middleName:null,surname:"Xiao",fullName:"Xinhua Xiao",slug:"xinhua-xiao"},{id:"138268",title:"Dr.",name:"Si",middleName:null,surname:"Chen",fullName:"Si Chen",slug:"si-chen"}]},{id:"23140",title:"Diabetes Control and Hypoglycemia",slug:"diabetes-control-and-hypoglycemia",totalDownloads:1932,totalCrossrefCites:0,signatures:"Paul Norwood and Alex Fogel",authors:[{id:"52801",title:"Dr.",name:"Paul",middleName:null,surname:"Norwood",fullName:"Paul Norwood",slug:"paul-norwood"},{id:"52805",title:"Mr",name:"Alexander",middleName:null,surname:"Fogel",fullName:"Alexander Fogel",slug:"alexander-fogel"}]}]},relatedBooks:[{type:"book",id:"338",title:"Hypoglycemia",subtitle:"Causes and Occurrences",isOpenForSubmission:!1,hash:"9d84665f80961e5d8e198fe59eec801d",slug:"hypoglycemia-causes-and-occurrences",bookSignature:"Everlon Cid Rigobelo",coverURL:"https://cdn.intechopen.com/books/images_new/338.jpg",editedByType:"Edited by",editors:[{id:"39553",title:"Prof.",name:"Everlon",surname:"Rigobelo",slug:"everlon-rigobelo",fullName:"Everlon Rigobelo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"},chapters:[{id:"21462",title:"A New Therapy of Type 2 Diabetes: DPP-4 Inhibitors",slug:"a-new-therapy-of-type-2-diabetes-dpp-4-inhibitors",signatures:"Tatjana Ábel",authors:[{id:"52763",title:"Dr.",name:"Tatjana",middleName:null,surname:"Ábel",fullName:"Tatjana Ábel",slug:"tatjana-abel"}]},{id:"21463",title:"Relationship Between Age and Diabetic Treatment Type on the Frequency of Hyperglycemic Episodes Monitored by Continuous Glucose Monitoring",slug:"relationship-between-age-and-diabetic-treatment-type-on-the-frequency-of-hyperglycemic-episodes-moni",signatures:"Boby G. Thekadeth, P. Zachariah, Zeenat Parveen, Pavan Patel, Matthew Schoeck, Andrew Mazulis, Lawrence Perlmuter and Sant P. Singh",authors:[{id:"46693",title:"Prof.",name:"Lawrence",middleName:null,surname:"Perlmuter",fullName:"Lawrence Perlmuter",slug:"lawrence-perlmuter"},{id:"57317",title:"Mr.",name:"Andrew",middleName:null,surname:"Mazulis",fullName:"Andrew Mazulis",slug:"andrew-mazulis"},{id:"57318",title:"Mr",name:"Pavan",middleName:null,surname:"Patel",fullName:"Pavan Patel",slug:"pavan-patel"},{id:"57319",title:"Mr",name:"Matthew",middleName:null,surname:"Schoeck",fullName:"Matthew Schoeck",slug:"matthew-schoeck"},{id:"57341",title:"Dr.",name:"Sant",middleName:"P",surname:"Singh",fullName:"Sant Singh",slug:"sant-singh"},{id:"106631",title:"Dr.",name:"Boby",middleName:null,surname:"Theckedath",fullName:"Boby Theckedath",slug:"boby-theckedath"},{id:"106633",title:"Dr.",name:"P.",middleName:null,surname:"Zachariah",fullName:"P. Zachariah",slug:"p.-zachariah"},{id:"106634",title:"Dr.",name:"Zeenat",middleName:null,surname:"Parveen",fullName:"Zeenat Parveen",slug:"zeenat-parveen"}]},{id:"21464",title:"Development of Mulberry Leaf Extract for Suppressing Postprandial Blood Glucose Elevation",slug:"development-of-mulberry-leaf-extract-for-suppressing-postprandial-blood-glucose-elevation",signatures:"Toshiyuki Kimura",authors:[{id:"60217",title:"PhD.",name:"Toshiyuki",middleName:null,surname:"Kimura",fullName:"Toshiyuki Kimura",slug:"toshiyuki-kimura"}]},{id:"21465",title:"Pathogenetic Mechanisms of Exercise-Associated Hypoglycemia: Permanent and Reversible Counterregulatory Failure",slug:"pathogenetic-mechanisms-of-exercise-associated-hypoglycemia-permanent-and-reversible-counterregulato",signatures:"Pietro Galassetti",authors:[{id:"41126",title:"Prof.",name:"Pietro",middleName:null,surname:"Galassetti",fullName:"Pietro Galassetti",slug:"pietro-galassetti"}]},{id:"21466",title:"An Update on Neonatal Hypoglycemia",slug:"an-update-on-neonatal-hypoglycemia",signatures:"Praveen Kumar and Shiv Sajan Saini",authors:[{id:"39845",title:"Prof.",name:"Praveen",middleName:null,surname:"Kumar",fullName:"Praveen Kumar",slug:"praveen-kumar"},{id:"104822",title:"Dr.",name:"Shiv Sajan",middleName:null,surname:"Saini",fullName:"Shiv Sajan Saini",slug:"shiv-sajan-saini"}]},{id:"21467",title:"Neonatal Hypoglycemia - Current Concepts",slug:"neonatal-hypoglycemia-current-concepts",signatures:"Blanca Álvarez Fernández and Irene Cuadrado Pérez",authors:[{id:"43139",title:"Ms",name:"Blanca",middleName:null,surname:"Alvarez Fernandez",fullName:"Blanca Alvarez Fernandez",slug:"blanca-alvarez-fernandez"},{id:"95652",title:"Mrs.",name:"Irene",middleName:null,surname:"Cuadrado Pérez",fullName:"Irene Cuadrado Pérez",slug:"irene-cuadrado-perez"}]},{id:"21468",title:"Glucose Infusions into Peripheral Veins in Neonates with Hypoglycemia",slug:"glucose-infusions-into-peripheral-veins-in-neonates-with-hypoglycemia",signatures:"Outi Tammela and Tarja Vanhatalo",authors:[{id:"45221",title:"Dr.",name:"Outi",middleName:"Kerttu Tellervo",surname:"Tammela",fullName:"Outi Tammela",slug:"outi-tammela"},{id:"135594",title:"Dr.",name:"Tarja",middleName:null,surname:"Vanhatalo-Suonurmi",fullName:"Tarja Vanhatalo-Suonurmi",slug:"tarja-vanhatalo-suonurmi"}]},{id:"21469",title:"Drug-Induced Hypoglycemia",slug:"drug-induced-hypoglycemia",signatures:"Kristen Helms and Kristi Kelley",authors:[{id:"53455",title:"Dr.",name:"Kristen",middleName:null,surname:"Helms",fullName:"Kristen Helms",slug:"kristen-helms"},{id:"58102",title:"Dr.",name:"Kristi",middleName:null,surname:"Kelley",fullName:"Kristi Kelley",slug:"kristi-kelley"}]},{id:"21470",title:"Drugs and Hypoglycemia",slug:"drugs-and-hypoglycemia",signatures:"Marek Pytliak, Viola Vargová and Viola Mechírova",authors:[{id:"39515",title:"Dr.",name:"Marek",middleName:null,surname:"Pytliak",fullName:"Marek Pytliak",slug:"marek-pytliak"},{id:"39520",title:"Dr.",name:"Viola",middleName:null,surname:"Vargova",fullName:"Viola Vargova",slug:"viola-vargova"},{id:"39521",title:"Prof.",name:"Viola",middleName:null,surname:"Mechirova",fullName:"Viola Mechirova",slug:"viola-mechirova"}]},{id:"21471",title:"Insulinoma – Diagnosis and Treatment",slug:"insulinoma-diagnosis-and-treatment",signatures:"Jan Škrha, Jaroslava Dušková, Jan Šváb, Jiřina Hilgertová, Josef Hořejš and Radan Keil",authors:[{id:"39596",title:"Prof.",name:"Jan",middleName:null,surname:"Škrha",fullName:"Jan Škrha",slug:"jan-skrha"},{id:"46210",title:"Prof.",name:"Jan",middleName:null,surname:"šváb",fullName:"Jan šváb",slug:"jan-svab"},{id:"46211",title:"Prof.",name:"Jaroslava",middleName:null,surname:"Dušková",fullName:"Jaroslava Dušková",slug:"jaroslava-duskova"},{id:"46212",title:"Dr.",name:"Jiřina",middleName:null,surname:"Hilgertová",fullName:"Jiřina Hilgertová",slug:"jirina-hilgertova"}]},{id:"21472",title:"Pancreatogenous Hypoglycemic Syndrome - Insulinoma or Non-Insulinoma Origin (NIPHS)",slug:"pancreatogenous-hypoglycemic-syndrome-insulinoma-or-non-insulinoma-origin-niphs-",signatures:"Chen-Hsen Lee, Justin Ging-Shing Won and Hsiao-Shan Tseng",authors:[{id:"41261",title:"Prof.",name:"Chen-Hsen",middleName:null,surname:"Lee",fullName:"Chen-Hsen Lee",slug:"chen-hsen-lee"},{id:"57644",title:"Dr.",name:"Justin Ginsing",middleName:null,surname:"Won",fullName:"Justin Ginsing Won",slug:"justin-ginsing-won"},{id:"57645",title:"Dr.",name:"Hsiu-San",middleName:null,surname:"Tseng",fullName:"Hsiu-San Tseng",slug:"hsiu-san-tseng"}]},{id:"21473",title:"Pancreatic Beta Cell Tumors",slug:"pancreatic-beta-cell-tumors",signatures:"M. Isabel del Olmo, J. Francisco Merino-Torres, J. Luis Ponce and Angel Moya",authors:[{id:"48001",title:"Dr.",name:"Juan Francisco",middleName:null,surname:"Merino-Torres",fullName:"Juan Francisco Merino-Torres",slug:"juan-francisco-merino-torres"},{id:"48009",title:"Dr.",name:"Maria Isabel",middleName:null,surname:"Del Olmo-Garcia",fullName:"Maria Isabel Del Olmo-Garcia",slug:"maria-isabel-del-olmo-garcia"},{id:"135588",title:"Dr.",name:"Luis",middleName:null,surname:"Ponce",fullName:"Luis Ponce",slug:"luis-ponce"},{id:"135590",title:"Dr.",name:"Angel",middleName:null,surname:"Moya",fullName:"Angel Moya",slug:"angel-moya"}]},{id:"21474",title:"Hypoglycemia Caused by Septicemia in Pigs",slug:"hypoglycemia-caused-by-septicemia-in-pigs",signatures:"Everlon Cid Rigobelo and Fernando Antonio de Ávila",authors:[{id:"39553",title:"Prof.",name:"Everlon",middleName:"Cid",surname:"Rigobelo",fullName:"Everlon Rigobelo",slug:"everlon-rigobelo"},{id:"62727",title:"Prof.",name:"Fernando Antonio",middleName:null,surname:"Avila",fullName:"Fernando Antonio Avila",slug:"fernando-antonio-avila"}]}]}]},onlineFirst:{chapter:{type:"chapter",id:"70160",title:"Microbiota, Inflammation, and Gut Barrier Dysfunction in HCC",doi:"10.5772/intechopen.89578",slug:"microbiota-inflammation-and-gut-barrier-dysfunction-in-hcc",body:'\nHighlights
Gut dysbiosis, inflammation, and increased intestinal permeability are synergistically contributed to the pathogenesis of hepatocellular carcinoma.
Previous studies in animal models suggest that targeting the gut-liver axis can inhibit HCC development.
Targeting the gut-liver axis with probiotics, antibiotics, FMT, TLR4 antagonists, FXR agonists, and natural compounds could be the promising strategies for HCC prevention.
Hepatocellular carcinoma (HCC) is a heterogeneous type of tumor that is likely to develop on the background of an inflammatory milieu in patients with advanced liver disease. It is the third leading cause of cancer death globally and is more prevalent in men than in women [1]. Over the past two decades, there is increasing evidence from studies suggesting a causal link between gut microbiota in the progression of HCC. Normal commensal gut microbiota acts as an important source of energy and is pivotal to host metabolism and innate immunity [2]. Not unsurprisingly therefore, alteration to gut microbial composition has been linked to the promotion of chronic inflammatory bowel disease (IBD) via local effects. However, activation of such inflammatory effects can have a broader response across all organ beds such as the liver, kidney, brain, heart, and the hematopoietic system and have been strongly associated with carcinogenesis [3]. Anatomical considerations provide us with a logical understanding on why gut microbiosis may have such an impact on disease development, especially in the liver. Since the liver is anatomically connected to the intestine via the portal vein, it is the first organ to receive nutrient-rich blood and also the first target of gut microbiota. Furthermore, the liver can elicit an inflammatory response through microbe-associated molecular patterns (MAMPs) and pattern recognition receptors (PRRs). Though translocation of gut microbiota from the intestinal lumen to the systemic circulation is counterchecked by multilayer intestinal epithelium, any change in its integrity can initiate inflammation and contribute to fibrosis and thus chronic liver disease (CLD) progression and thus a precursor to HCC development, which is itself usually only seen in the context of cirrhosis, the most advanced form of CLD [4]. In this chapter, we summarize the available literature on the key role of gut microbiome in HCC pathogenesis and novel therapeutic approaches developed to target these processes.
\nThe gut microbiota resides in the gastrointestinal (GI) tract. The human gut harbors complex and diverse microbial community of 100 trillion microorganisms with more than 2000 distinct species of bacteria, in addition to fungi protozoans and viruses. These microorganisms are collectively called gut microbiota, which comprises of commensals, beneficial microbiota, and opportunistic pathogens residing in what is a complex and dense microenvironment. Immediately after birth commensal bacteria colonize the intestine and predominantly comprise Proteobacteria, Lactobacillus, and Actinobacteria, but as we mature into adults Bacteroidetes and Firmicutes species predominate [5]. The composition of microbiota also varies from the small intestine to the distal colon, due largely to the effects of nutrient availability, intestinal pH, and motility. Moreover the overall composition of the microbial community in the gut is further individualized by any alteration in our diet, age, lifestyle, disease, and also medication exposure [6]. A symbiotic relationship exists between gut microbiota and the human host, which are critical to our maintenance of health. For example, gut microbiota are involved in the metabolism of bile acids, synthesis of vitamins, digestion of complex polysaccharides, and production of short-chain fatty acids (SCFAs) [2]. SCFAs are a vital source of energy for enterocytes, which are integral in maintaining gut barrier integrity. In addition, gut microbiota are also involved in the development of local and innate immunity providing defense against not only the pathogenic invasion but also systemic infection [7]. Experimental studies from rodents and humans have demonstrated that the gut microbiota is involved in the progression of HCC by increasing LPS-mediated pro-inflammatory microenvironment in the liver.
\nGut microbiota are known to influence multiple extraintestinal organs; however the importance of the gut-liver axis has understandably received greater attention in recent years. The gut and liver share anatomy from the embryonic phase, with bidirectional interaction through the portal vein. The symbiotic relationship between the gut microbiota and the liver is modulated by the nutrition, immune, metabolic, and neuroendocrine crosstalk between them and thus shapes human health and disease [8]. Functionally, gut and liver coordination influences our physiology. The liver receives 70% of the blood supply from the gut via the portal circulation. The nutrient-rich blood from the gut is effectively processed by the liver and delivered to systemic circulation for normal body growth. In turn, the liver synthesizes bile acids (BAs) and other mediators, like IgA, which influence intestinal microbial composition and barrier integrity, thereby maintaining intestinal homeostasis [8]. Bile acids are involved in energy homeostasis by regulating the metabolism of glucose and lipids and also help in conjugation and detoxification process as well as maintenance of intact intestinal epithelia. Bile acids also regulate microbial composition via antimicrobial peptides production; in turn, microbiota influences the bile acid pool in the intestine as they are involved in secondary bile acid production [9]. IgA secreted from the liver and intestine prevents growth and invasion of pathogenic bacteria to maintain normal gut-liver homeostasis [7]. In normal physiological conditions, translocation of gut bacteria and their metabolites is tightly regulated by the intestinal epithelial barrier, and if any reaches the liver, it is eliminated by hepatic Kupffer cells. Any breach in barrier integrity resulting from intestinal inflammation allows microbiota to pass through the portal vein to potentially trigger hepatic immune cells to enact an inflammatory response (from hepatic stellate cells and Kupffer cells), which may result in necrotic inflammation and hepatic fibrosis contributing to worsening fibrosis and thus liver disease progression [10]. Accumulating evidence suggests gut dysbiosis, bacterial endotoxin, and increased intestinal permeability are hallmark features of CLD and positively correlate with disease severity. These factors play a crucial role in the pathogenesis of not only CLD but have also been shown to promote HCC through various mechanisms (Figure 1).
\nAn overview of homeostatic and impaired gut-liver axis in HCC progression. (A) In homeostatic condition gut lumen contains normal gut flora which is restricted by tightly closed intestinal epithelial cells to prevent its translocation to the liver. (B) Increased bacterial overgrowth in gut lumen and increased intestinal permeability promotes HCC progression through binding of LPS to toll-like receptor 4 (TLR4) which are present on Kupffer cells, hepatocytes, and HSC to elicit the release of pro-inflammatory cytokines and activation of proliferative and anti-apoptotic signals. Prebiotics, probiotics, synbiotics, FMT, and polyphenols can be used to restore eubiosis, while the use of antibiotics can potentially eliminate pathogenic bacteria and endotoxin release. FXR agonists can attenuate intestinal permeability and prevent bacterial translocation. TLR4 antagonists prevent binding of LPS to TLR4 and suppress cancer-promoting signals.
Dysbiosis defines any change in the typical gut microbial composition found in health. Several lines of evidence suggest that gut bacterial dysbiosis is a pathogenic factor in the progression of HCC whatever the trigger for CLD (e.g., alcohol, nonalcoholic steatohepatitis (NASH), viral hepatitis, etc.). The role of gut dysbiosis in the propagation of progressive CLD is likely triggered by the formation of microbial metabolites such as LPS, bacterial DNA, and deoxycholic acid, which causes chronic inflammation in the portal circulation and thus the liver. In cirrhotic patients overgrowth of the pathogenic bacteria such as Enterobacteriaceae, Veillonellaceae, and Streptococcaceae and decreased Lachnospiraceae have been observed to correlate with the child-turcotte-pugh (CTP) score, clinically used to assess the severity of cirrhosis [11]. Moreover, in cirrhotic patients studies have found an increase in both the oral and gut levels of the same microbial species suggesting invasion from the mouth to intestine [12]. It is therefore postulated oral bacterial overgrowth may have a profound effect on intestinal bacterial communities and thus CLD pathogenesis and HCC development. This concept is supported by a recent study that showed a high level of oral microbiota Oribacterium and Fusobacterium in HCC patients [13]. The alteration in gut microbiota composition in HCC is summarized in Table 1.
\nAuthors | \nSample type | \nChanges in fecal microbiota composition | \nClinical implication in HCC | \n
---|---|---|---|
Ren et al. [14] | \nFeces | \nKlebsiella i | \n\n
| \n
Ponziani et al. [15] | \nFeces | \nBacteroides ↑ Ruminococcaceae ↑ Enterococcus ↑ Phascolarctobacterium ↑ Oscillospira ↑ Bifidobacterium ↓ Blautia ↓ | \n\n
| \n
Grat et al. [16] | \nFeces | \nEscherichia coli ↑ | \n\n
| \n
Huang et al. [18] | \nHCC liver biopsy | \nHelicobacter pylori ↑ | \n\n
| \n
Zhang et al. [19] | \nFeces | \nEscherichia coli ↑ Atopobium cluster ↓ Prevotella ↓ Bacteroides ↑ Lactobacillus spp. ↑ Bifidobacterium spp. ↑ Enterococcus spp. ↓ | \n\n
| \n
Yoshimoto et al. [38] | \nFeces | \nClostridium cluster XI and XIVa ↑ | \n\n
| \n
Gut microbiota dysbiosis in HCC.
Microbial gene signatures that relate to energy production, nickel/iron transport, and amino acid transport appear to be altered in HCC patients when compared to healthy controls [13]. Moreover, when compared to cirrhotic patients, fecal samples from HCC patients have shown increased growth of phylum Actinobacteria and 13 genera including Gemmiger and Parabacteroides [14]. They also found a decrease in butyrate-producing bacteria and an increase in LPS-producing bacteria in HCC patients when compared to healthy controls [14]. A study conducted by Ponziani et al. in NAFLD-related HCC showed increased fecal Bacteroides and Ruminococcaceae, whereas reduced Akkermansia and Bifidobacterium were negatively correlated with intestinal inflammatory marker fecal calprotectin level [15]. This study also showed increased intestinal permeability in these patients accompanied by an increase in plasma level of IL8, IL13, CCL3, CCL4, and CCL5, showing the evidence that alteration in gut microbiota profile is associated with systemic inflammation that may contribute to HCC pathogenesis [15]. In another study, E. coli growth in fecal samples was significantly elevated in HCC patients compared to matched cirrhotic patients [16]. Interestingly, inoculation of AFB1 and/or Helicobacter hepaticus in Helicobacter-free C3H/HeN mice was associated with HCC progression [17]. This observation may suggest that neither direct bacterial translocation nor hepatocyte injury is necessary for HCC development. In clinical studies utilizing liver HCC tumor biopsy tissue, some authors report the presence of Helicobacter ssp. DNA, whereas other investigators failed to correlate the presence of Helicobacter ssp. DNA with HCC progression [18]. In DEN-treated rats, fecal and cecal samples show an increase of pathogenic bacterial species like E. coli, Atopobium, Collinsella, Eggerthella, and Corynebacterium; in contrast there was a decline in the numbers of beneficial bacteria like Lactobacillus spp., Bifidobacterium spp., and Enterococcus spp. [19]. Although the exact mechanism by which gut microbiota promotes HCC has not been firmly established, studies in murine models indicated LPS-TLR4 axis plays a crucial role in the progression of HCC [19, 20]. Zhang et al. suggest that gut dysbiosis merely promotes HCC by increasing LPS levels and that conversely probiotics may suppresses tumor growth [19]. Similarly, Dapito et al. propose that gut microbiota only has a role in the promotion of HCC rather than its initiation [20]. The ability of pathogenic bacteria to disrupt TJs protein thereby increasing intestinal permeability has also been postulated as another mechanism by which microbiota may promote CLD and HCC [21]. However further preclinical and clinical studies are needed to establish the causal link between gut microbiota and HCC progression and to further delineate the molecular mechanisms involved.
\nHCC is arising in an inflammatory environment of the CLD, and therefore, neutralizing inflammation with anti-inflammatory agents may reduce the incidence and recurrence of HCC. Much attention has been focused on the potential involvement of the toll-like receptors (TLR) signaling pathway in the development of liver inflammation and associated HCC progression. Gut-derived endotoxin initiates the innate immune system such as TLRs, which recognize bacterial products and are predominantly expressed throughout the gut-liver axis. In addition, TLR4 plays a central role through LPS (a component of Gram-negative bacteria)-induced hepatic inflammation, while TLR 2 senses component of Gram-positive bacteria such as peptidoglycan [22]. In this context, Yu et al. identified that increased activation of the TLR 4-LPS axis correlated with intestinal permeability in DEN-induced acute liver failure (ALF), which directly regulates pro-survival molecules and enhances hepatocyte proliferation [23]. Interestingly, in mice models the use of antibiotics and/or TLR4 genetic ablation prevented tumor growth and multiplicity [19, 23]. Dapito et al. showed a close link between gut microbiota and LPS-TLR 4 axis in HCC progression in a chimeric mice model [20]. This study also showed in DEN-CCl4 treated mice (with histological CLD) that low-dose LPS treatment triggered TLR4 activation and increased rate of tumor formation, whereas gut sterilization prevented HCC progression rather than regression of the established tumor [20]. Taken together these studies would therefore suggest that gut microbiota may not have a role in HCC initiation but may instead have a tumor-promoting effect through TLRs signaling pathways [20].
\nIn respect of HCC promotion, multiple downstream targets of the LPS-TLR4 axis have been identified in both in vitro and in vivo studies. HSCs, Kupffer cells, and hepatocytes show TLR4 expression and thus are sensitive to LPS challenge [24]. Dapito et al. showed that TLR4 activation in HSCs, hepatocytes, and non-bone-marrow-derived resident cells promotes hepatocarcinogenesis by upregulating epiregulin (hepatomitogen) and inhibiting cleaved caspase 3 via NF-κB activation [20]. Moreover, Yu et al. showed hepatic Kupffer cells as the chief target for LPS-induced TLR4 activation by increasing pro-inflammatory cytokines such as TNF-α and IL-6 production [23]. Similarly, in vitro studies have shown evidence of LPS-TLR4-promoted HCC cell proliferation via NF-κB, MAPK, and STAT3 mediated signaling pathways [24]. LPS-TLR4 has also been shown to promote epithelial-to-mesenchymal transition (EMT) in HCC by upregulating NF-κB- and JNK/MAPK-mediated expression, while NF-κB and JNK/MAPK signaling blockade inhibited EMT occurrence [25]. Similarly, LPS-TLR4 axis is also known to enhance angiogenesis in HCC mice model via production of pro-angiogenic factors by HSCs in tumor stroma [26]. However further studies incorporating TLR4 deletion are needed to better understand its role in hepatocyte proliferation and distinguish paracrine signaling from HSCs and Kupffer cells in HCC progression.
\nCommensals and opportunistic pathogens are kept in check within the intestinal lumen by a single layer of intestinal epithelial cells (IEC) which spans almost 400 m2 in surface area [27]. The gut barrier is highly dynamic in nature in which IEC is capable of self-renewal every 4–7 days with constant changes in intestinal luminal content. IEC are predominantly composed of absorptive enterocytes, which have metabolic and digestive functions. It also has secretory functions enacted by cell types such as enteroendocrine, goblet, and paneth cells which are specialized for maintaining digestive, immune, and epithelial barrier function [27]. Enteroendocrine cells connect the central and enteric neuroendocrine system via the secretion of various digestive hormones like gastrin, cholecystokinin, incretin, etc. The highly glycosylated mucins secreted by goblet cells form the first line of defense against microbial invasion and when compromised may predispose to disease as is evident in Mucin 2-deficient mice which are susceptible to colitis and inflammation-induced colorectal cancer [28, 29]. The intestinal barrier function is further strengthened by antimicrobial peptides (AMPs) including defensin, cathelicidin, and lysozyme [27]. These AMPs disrupt bacterial cell membranes and prevent adherence to gut mucosa.
\nApart from IEC, the gut barrier is primarily maintained by tight junction (TJs) components (e.g., claudin, occludin, zonula occludens, and other junctional adhesion molecules (JAMs)) preserving intact epithelia which in turn regulate the paracellular movement of solutes, water, and other nutrients while restricting the entry of bacteria from the lumen to systemic circulation [30]. The mechanism of increased intestinal permeability is poorly understood. Growing evidence suggests that inflammation and TJ protein disruption are two of the key players driving increased intestinal permeability. In our previous study, we found increased systemic ZO-1 level in HCC patients reflecting increased intestinal permeability [31]. Moreover, plasma ZO-1 level was positively correlated with the inflammatory marker hs-CRP and with disease severity, suggesting inflammation drives intestinal permeability associated with HCC progression [31]. Bacterial overgrowth leads to increased production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β, which is mainly mediated through the TLR4-NF-kB signaling pathway, thereby promoting intestinal inflammation and HCC progression [19]. These pro-inflammatory cytokines have a direct effect on TJ proteins like claudin and ZO-1, leading to enhance intestinal permeability [32]. Furthermore, in both in vivo and in vitro models, LPS dose dependently increases intestinal permeability via upregulating TLR4-mediated CD14 expression in enterocytes [33]. Similarly, NLRP6-deficient mice show altered microbiota and enhanced colonic inflammation through the chemokine (C-C motif) ligand CCL5 [34]. This results in increased intestinal permeability to microbial products and thus increases hepatic inflammation and progression from NAFLD to NASH [34]. Moreover, enteric pathogens such as Escherichia coli and Clostridium difficile are increased in CLD and are capable of increased intestinal permeability by modulating TJ integrity [11, 21].
\nBile acids are another key player for maintaining gut barrier function by promoting intestinal epithelial cell proliferation and microbiota composition [35]. There is clear evidence that bile acids have both direct antimicrobial effect and an indirect effect through FXR-induced AMPs and thus control growth and adhesion of intestinal bacteria. In fact, decreased bile acids pool in the intestine is associated with bacterial overgrowth and inflammation [36]. The study by Kakiyama et al. showed that cirrhosis reduced bile acids entering the intestine causing bacterial dysbiosis by reducing beneficial bacteria such as Gram-positive Blautia and Ruminococcaceae and increasing pathogenic bacteria like Enterobacteriaceae [37]. In a NASH-induced CLD/HCC mouse model, increased Gram-positive Clostridium clusters (XI and XVIa) were positively correlated with increased serum deoxycholic acid (DCA) [38]. Notably, Clostridium clusters are capable of synthesis of secondary bile acid DCA via 7α-dehydroxylation of primary bile acids. DCA is a DNA-damaging agent and a known pro-carcinogen shown to affect various cancer signaling pathways. In this context, a study by Yoshimoto et al. revealed DCA activates a senescent-associated secretory phenotype in HSCs, thereby producing various pro-inflammatory and pro-tumorigenic factors promoting HCC development in mice, while antibiotic treatment and/or blocking DCA production prevented HCC development [38]. Similarly, in a HCC mouse model induced by steatohepatitis-inducing high-fat diet (STHD-01), increased hepatic and fecal bile acids concentrations were observed [39]. In this model, DCA activated mTOR and promoted HCC development. However, following antibiotic treatment, there was a decrease in HCC progression suggesting an interrelationship between BA metabolism, gut microbiota, and HCC development [39].
\nBile acids maintain homeostatic IEC proliferation via EGFR- and FXR-dependent pathways, which helps the continuous regeneration of enterocytes and maintain intact epithelia [40]. Several studies demonstrate that the intestinal bile acid pool also regulates TJ protein distribution and expression. In Caco-2 cell monolayers, incubation with dihydroxy bile acids decreased transepithelial resistance (TER) and was accompanied by increased phosphorylation and redistribution of occludin [41]. In human colonic biopsies, DCA induces Cr-EDTA permeability altering TER and increasing translocation of E. coli. Several in vivo studies have also elucidated the role of bile acids in the regulation of TJ permeability [42]. In HFD mice increased intestinal bile acid pool was associated with increased intestinal permeability with decreased expression of TJ proteins ZO-2 and JAM-A [43]. Similarly, in bile duct ligated (BDL) rats where intestinal BA delivery was prevented, there was increased bacterial translocation and increased intestinal permeability with decreased expression of claudin-1 and occludin. Conversely, the above effects were ameliorated by FXR activation [44]. These studies highlighted the protective role of FXR in the maintenance of intestinal barrier integrity; however, it is unclear whether these effects were from direct activation of FXR on TJ proteins or indirect effects from altered mucosal immune cells. In addition to FXR, another bile acid receptor TGR5 also modulates barrier permeability and TJ protein expression. In TGR5 null mice, increased intestinal permeability due to alteration of TJ protein expression develops colitis [45]. Therefore, the quantity and composition of BA pool in the intestine represent an important factor in the regulation of gut microbial community and gut barrier integrity.
\nTraditionally, HCC is cured based on the available treatment options such as surgical treatment, chemotherapy, and local ablation therapy; however, patients are facing many problems including the poor hepatic reserve [46]. Furthermore, the possible therapeutic interventions targeting the gut-liver axis in HCC are summarized in Table 2.
\nAuthors | \nIntervention class | \nMedication | \nDesired effect in HCC | \n
---|---|---|---|
Zong et al. [53] | \nPrebiotics | \nLactulose | \n\n
| \n
Zhang et al. [19] | \nProbiotics | \nVSL#3 | \n\n
| \n
El-Nezami et al. [63] | \nProbiotics | \nLactobacillus rhamnosus LC 705 and Propionibacterium freudenreichii subsp. shermani | \n\n
| \n
Li et al. [46] | \nProbiotics | \nProhep | \n\n
| \n
Kumar et al. [62] | \nProbiotics | \nCombination of probiotic fermented milk and chlorophyllin | \n\n
| \n
Yoshimoto et al. [38] | \nAntibiotics | \n4Abx (ampicillin, metronidazole, vancomycin, neomycin) | \n\n
| \n
Abdel-Hamid et al. [67] | \nAntibiotics | \nClarithromycin and azithromycin | \n\n
| \n
Dapito et al. [20] | \nAntibiotics | \nRifaximin | \n\n
| \n
Nguyen et al. [93] | \nTLR4 antagonists | \nTAK-242 | \n\n
| \n
Nkontchou et al. [117] | \nNonselective β-blockers | \nPropranolol | \n\n
| \n
Chang et al. [118] | \nNonselective β-blockers | \nPropranolol | \n\n
| \n
Bishayee et al. [121] | \nNatural compound | \nResveratrol | \n\n
| \n
Ji et al. [124] | \nNatural compound | \nQuercetin | \n\n
| \n
Teng et al. [125] | \nNatural compound | \nCurcumin | \n\n
| \n
Therapeutic intervention targeting the gut-liver axis in HCC.
Prebiotics are non-absorbant and nondigestible food ingredients which promote growth or activity of beneficial bacteria like Bifidobacteria and Lactobacilli and inhibit the growth of potentially pathogenic bacteria [47]. Currently, prebiotics like lactulose, lactitol, fructo-oligosaccharides, and galacto-oligosaccharides are commercially available [48]. Synthetic disaccharides like lactulose and lactitol are extensively used for the treatment of hepatic encephalopathy in CLD patients as ammonia detoxifying agents [48]. Also, these disaccharides are metabolized by colonic bacteria to produce lactic acid and acetic acid due to which pH in the gut lumen is decreased [49]. Low pH enhances the growth of non-urease-producing lactobacilli and inhibits pathogenic urease-producing bacteria [50]. Chen et al. showed that in chronic viral hepatitis patients, lactitol administration significantly decreased plasma endotoxin levels and increased the growth of beneficial Lactobacilli and Bifidobacteria species [51]. In contrast, Bajaj et al. reported lactulose administration in patients with HE did not improve dysbiosis and increased growth of Gram-negative bacteria such as Enterobacteriaceae and Bacteroidaceae [52]. This indicates the pattern of gut microbiota abundance is the major determinants of disease severity [52]. In HCC patients administration of lactulose (30 mL/day) for 14 days significantly reduced ALT and bilirubin levels, while antioxidant enzyme SOD, anti-inflammatory markers IFN-γ and IL-4, and blood cells CD4(+)/CD8(+) were found to be increased suggesting its ability to reduce inflammation and restore oxidation/antioxidant system imbalance [53]. Similarly in partial hepatectomized rats, administration of lactulose induces liver regeneration by inducing hydrogen and abrogating oxidative stress (heme oxygenase-1, SOD-2) and inflammation (IL-6 and TNF-α) [54]. Moreover, mixed diets of galacto-oligosaccharides and fructo-oligosaccharides to infants were increased the growth of Bifidobacterium; however, this formulation has not been tried in patients with liver disease [55].
\nProbiotics are live microorganisms which when administered in adequate amounts confer a health benefit for the host [56]. Probiotic supplementation was also shown to restore intestinal dysbiosis in CLD patients [48]. Furthermore, mice treated with probiotic such as VSL#3 significantly reduces Clostridium spp. and modified gut microbiota [57]. In cirrhotic patients, VSL#3 supplementation for nearly 6 months was shown to reduce the risk of hospitalization and improved CTP and MELD score [58]. Similarly, in NASH-associated obese children, treatment with VSL#3 over the period of 4 months reduces fatty liver and improved lipid profile and insulin sensitivity [59]. The other probiotics such as Lactobacillus salivarius LI01 and Pediococcus pentosaceus LI05 reduced inflammation, protected the intestinal barrier, prevented bacterial translocation, restored eubiosis, and attenuated hepatic fibrosis in CCl4-induced cirrhotic rats [60]. Similarly, Lactobacillus GG (LGG) supplemented with standard diet in cirrhosis patients show significantly reduced blood endotoxemia and TNF-α, thereby restoring eubiosis [61]. However, in HCC, probiotic usage is meager, and only a few studies have identified the therapeutic potential. VSL#3 (contains three strains of Bifidobacteria, four strains of Lactobacilli, and one strain of Streptococcus thermophilus) treatment to DEN-induced rat hepatocarcinogenesis has shown to attenuate HCC progression, reduce tumor number and multiplicity, ameliorate hepatic and intestinal inflammation, and thus restore gut dysbiosis [19]. Li et al. identified that subcutaneous administration of Prohep (a novel probiotic mixture of Lactobacillus rhamnosus GG, Escherichia coli Nissle 1917, and heat-inactivated VSL#3) reduced the tumor size and HCC growth [46]. Prohep improves beneficial bacteria such as Prevotella and Oscillibacter and control tissue inflammation as evidenced by decreased T helper 17 cells in the gut, thereby attenuating the progression of HCC [46]. Moreover, in aflatoxin B1-induced HCC rats, treatment with probiotic fermented milk and chlorophyllin significantly reduced tumor incidence by decreasing the expression of cyclin D1, bcl-2, and c-myc proto-oncogenes [62]. Similarly, aflatoxin-induced HCC patients treated with dietary supplementation of probiotics (using viable Lactobacillus rhamnosus LC 705 and Propionibacterium freudenreichii subsp. shermani) decreased the urinary excretion of aflatoxin-DNA adduct (AFB-N7 guanine) and improved HCC [63]. Thus, probiotic supplementation could be beneficial to cirrhotic patients with the potential to progress to HCC.
\nSynbiotics are combined form of prebiotics and probiotics, which contains four fermentable fibers (symbiotic 2000) and four freeze-dried non-urease-producing lactic acid bacteria. Synbiotic administration to cirrhotic patients results in decreased plasma endotoxin and ammonia levels and increased fecal Lactobacillus spp. [64]. Interestingly 50% of these patients have improved child-turcotte-pugh score compared to placebo [64]. Moreover, in NAFLD patients synbiotic supplementation has shown to have beneficial effects by improving lipid profile, glucose homeostasis, hepatic marker enzymes, and inflammatory markers [65]. Synbiotic (FloraGuard) administration also has a protective role in alcohol-induced liver injury in rats [66]. In addition, the synbiotic treatment restored ethanol-induced intestinal permeability and increased the growth of beneficial bacteria Bifidobacterium spp. and Lactobacillus spp. [66]. Currently, studies are lacking for the use of synbiotics in chronic liver diseases or HCC prevention.
\nSeveral studies have postulated that antibiotic treatment may cause gut microbiota dysbiosis. It may represent effective strategies to prevent the tumor-promoting gut microbiota, its metabolites DCA, and pro-inflammatory signal inducer LPS which all have a role in the progression of CLD and HCC. In DEN-CCl4- and DMBA-HFD-induced HCC mice model, the oral antibiotics ampicillin, metronidazole, neomycin, and vancomycin significantly reduced the tumor number and size [20, 38]. In addition, this antibiotic combination also reduced the liver fibrosis and improved liver histology in cirrhosis. Moreover, the effectiveness of antibiotics administration was enhanced when given at late-stage HCC in mice rather than earlier stage [20]. In another study conducted in DEN-induced HCC rats, clarithromycin and azithromycin suppressed HCC progression through extrinsic and intrinsic apoptotic pathways, whereas erythromycin aggravated HCC and did not show antitumorigenic effect [67]. Vancomycin is an antibiotic used to treat a bacterial infection, which effectively prevented the mouse model of HCC; however, long-term administration to CLD patients develops potential side effects [38]. Many studies have concluded that norfloxacin and rifaximin treatments to cirrhotic patients have beneficial effects [68]. In a double-blind placebo-controlled clinical trial, long-term oral administration of norfloxacin to cirrhotic patients markedly reduces Gram-negative bacteria in the fecal matters and lowers the spontaneous bacterial peritonitis (SBP) [69]. Furthermore, CCl4-induced cirrhotic animals showed decreased SBP and inflammation following norfloxacin treatment [70]. Norfloxacin was identified as a promising antibiotic in regulating gut microbiota overgrowth and prevention of BT in both cirrhotic humans and rodents; indeed its effect on HCC patients remains unidentified. Rifaximin is a broad spectrum oral antibiotic having potential bactericidal activity against aerobic and anaerobic Gram-negative bacteria [71]. It is an excellent choice of drug to cure HE in advanced cirrhotic patients [72]. The study conducted by Vlachogiannakos et al. showed treatment with rifaximin for 4 weeks significantly decreased portal pressure and LPS levels in decompensated cirrhotic patients [73]. Long-term treatment with rifaximin reduces SBP occurrence, variceal bleeding, HRS, and HE with an overall improvement in survival rate in cirrhotic patients [74]. Similarly, in murine DEN-CCl4-induced HCC mouse model, rifaximin treatment was shown to ameliorate HCC progression [20]. Although rifaximin is clinically used for prevention of HE and other complications in cirrhotic patients, its role in HCC prevention in humans is further warranted.
\nFecal microbiota transplantation is currently being used for the treatment of Clostridium difficile infection [75]. The enteric dysbiosis was restored to normal gut flora following FMT from healthy donor to Clostridium difficile-infected patients [75]. Moreover, in mice with gut dysbiosis induced by antibiotics and chemotherapy, treatments were reversed by FMT [76]. In experimental cirrhosis with hepatic encephalopathy, FMT improves liver function and HE grade by limiting inflammation and improving tight junction integrity [77]. In this context, Bajaj et al. reported that FMT in cirrhotic patients with recurrent HE improves cognition, restores dysbiosis, and improves MELD score compared to standard care in those patients [78]. A number of clinical trials are ongoing in patients with NASH and cirrhosis for the efficacy of FMT [79, 80]. Vrieze et al. reported in patients with severe metabolic syndrome that treatment with FMT from a healthy donor improves liver biochemistry, peripheral insulin resistance, and restoration of eubiosis [81]. Furthermore, in alcoholic hepatitis patients, FMT treatment significantly reduced liver disease severity and HE occurrence [82]. FMT recipients also showed an increase in beneficial bacteria like Actinobacteria and Bifidobacterium longum and decrease in Pseudomonas and E. coli with an increase in bile secretion [82]. Collectively these findings indicated that FMT may restore gut dysbiosis and reduce complications in cirrhotic patients and thus attenuate HCC development. However, scarce literature supporting the beneficial effect of FMT and long-term study is needed to prove permanent colonization in altered gut microbiota environment in cirrhotic patients. Moreover, there is a chance of inducing viral infection and transmission of other pathogens through FMT which may have deleterious effect and immunosuppression in advanced liver disease patients [83, 84].
\nNumerous studies have shown that LPS-TLR4 is a key inflammatory pathway in the progression of CLD and has a tumor-promoting effect on HCC [20, 23, 85]. Therefore blocking this pathway might represent a promising treatment approach in controlling cirrhosis and HCC progression. Several TLR4 antagonists have been developed toward controlling LPS-activated TLR4-mediated inflammatory responses which include polymyxin B [86], glycolipids interfering CD14-LPS interaction [87], eritoran [88], resatorvid (TAK242) [89], and thalidomide [90]. In BDL-induced cirrhotic rats, intravenous administration of TAK-242 significantly reduces plasma transaminases and inflammatory cytokines [91]. It also ameliorates acetaminophen-induced acute liver failure [92]. Similarly, in transgenic HCC mice (HepPten−), TAK-242 treatment for 28 days significantly reduced tumor burden and ameliorated HCC progression [93]. Eritoran tetrasodium protects against liver ischemia/reperfusion injury by inhibiting inflammatory response induced by high-mobility group box protein B1 (HMGB1) [94]. Similarly in D-galactosamine- and LPS-induced acute liver failure, treatment with eritoran significantly reduces inflammation and hepatic marker enzymes [95]. Eritoran treatment also decreases proliferation and induces apoptosis in tumor cells in a chemically induced mouse model of colorectal carcinoma [96]. Although resatorvid and eritoran showed the beneficial effect in improving the survival of murine sepsis model, it failed to do so in patients with severe sepsis [97]. Several TLRs have been upregulated in HCC [98]. In addition, TLRs are also abundantly expressed on immune cells which recognize various pathogens such as HBV which upon activation induces an innate immune response [99]. All the TLRs are activated by two independent pathways: MyD88-dependent (except TLR3) and MyD88-independent (TLR3 and TLR4) pathway [100]. Activation of TLR3-TRIF signaling pathway leads to apoptotic activity independently and, in turn, also activates IRF3 transcription factor to produce interferons [100]. TLR3 agonist BM-06 (synthetic dsRNA) significantly inhibited HCC cell proliferation, increased apoptosis, and decreased cell invasion and migration with increased antiviral IFN level [101]. Activation of TLR9 leads to phosphorylation of NF-κB with increased production of pro-inflammatory cytokine TNF-α, IL-6, and IL-10 [102]. Mohamed et al. showed that inhibition of TLR7 and TLR9 with antagonist IRS-954 or chloroquine significantly reduces HCC cell proliferation, angiogenesis with increased apoptosis [103]. This was further supported by tumor xenograft and DEN-induced rat HCC model in which chloroquine treatment reduces HCC incidence [103]. Although growing evidence shows TLRs as an important mediator of HCC progression, the molecular mechanism for disease progression is not completely understood. Therefore, further research needs to be done for the use of TLR agonist or antagonist as a drug target for HCC prevention since TLRs are also involved in both cancer-promoting mechanism and immune-modulator which is responsible for an innate immune response against tumor cells and HBV and HCV infection [99, 104, 105, 106].
\nBacterial overgrowth due to impaired gut motility has been reported in cirrhotic patients [107]. Cisapride, a prokinetic drug, has shown beneficial effects not only by regulating intestinal motility but also inhibiting bacterial overgrowth and preventing bacterial translocation in both rodent models and liver cirrhotic patients [108, 109]. Cisapride in combination with norfloxacin significantly reduces the incidence of SBP in high-risk cirrhotic patients [110]. Although the mechanism of impaired gastrointestinal motility in cirrhotic patients is unclear, increased adrenergic activity may be responsible for the altered motility.
\nNonselective β-blockers are prevalently used in decompensated chronic liver disease patients to reduce morbidity and mortality. It is used as bleeding prophylaxis in cirrhotic patients with esophageal varices. NSBB also antagonizes β-adrenoceptors. The β-adrenergic receptor pathway is involved in maintaining normal physiological functions. The catecholamines such as epinephrine and norepinephrine are the key ligands for β-adrenoceptors (β1 and β2). Furthermore, increased expression of β-adrenoceptors was observed in HCC cell membranes compared to healthy liver cells; however, the mechanisms remain unclear [111]. Catecholamines exhibit pro-carcinogenic effects in gastric, pancreatic, and breast cancer, which is antagonized by NSBB. Its beneficial effects to reduce the risk of HCC have also been identified by the very recent observational and experimental trials [112]. Moreover, in ovarian and breast cancer patients, NSBB treatment was shown to reduce cancer formation and growth. In cirrhotic patients, increased catecholamines results in disease severity, and thus, NSBB treatment may be potent to inhibit carcinogenesis in cirrhosis [113]. A recent study by Leithead et al. showed NSBB is safe and may confer benefit in patients with ascites complicating the end-stage liver disease [114]. In addition, Reiberger et al. observed that NSBB treatment ameliorates intestinal permeability and reduces BT in cirrhotic patients [115]. In a recent study, Wang et al. showed propranolol induces apoptosis and suppresses proliferation of liver cancer cells [116]. Of note, long-term treatment with propranolol in patients with HCV-related cirrhosis reduces the incidence of HCC [117]. Similarly, in patients with unresectable/metastatic HCC cohort, propranolol treatment significantly reduces mortality risk and improved overall survival suggesting β-blockers might be another therapeutic approach in HCC prevention [118].
\nTreatment with natural compounds and food ingredients like polyphenols represents another therapeutic approach in the restoration of eubiosis, modulation of gut microbiota, reduction of inflammation, prevention of cirrhosis, and thus the progression of HCC. Many experimental data have shown evidence that flavonoids are proficient to alter gut microbial composition and restoration of eubiosis in chronic liver diseases. Proanthocyanidin improves beneficial microbiota Bacteroides such as Lactobacillus spp. and Bifidobacterium spp. composition and reduces intestinal inflammation and oxidative damage, thereby attenuating experimental colon cancer. Resveratrol, a flavonoid, is shown to modulate intestinal microbiota with a profound increase in Bifidobacterium spp. and Lactobacillus spp. and reduce systemic and colonic inflammation in rats [119]. Resveratrol also shown to have anticancer activity in HCC cell lines; inhibit proliferation, viability, invasion, and metastasis; and induce apoptosis [120]. Its anticancer property was also studied in DEN-induced hepatocarcinogenesis [121]. We found resveratrol treatment to cirrhotic mice attenuated systemic inflammation and ammonia levels and altered neuronal TJ proteins, thereby preventing secondary complications such as HE in cirrhosis [122]. Quercetin, a bioactive flavonoid, was shown to inhibit human HCC cell proliferation, migration, and invasion and trigger apoptosis both in vivo and in vitro [123]. Its profound antitumor effect was also shown in xenograft and DEN-induced HCC rodent models [124]. Curcumin, a powerful antioxidant, has a wide range of bioactive properties. Previous studies have shown evidence that curcumin has HCC chemoprevention in preclinical models as well as patients with HCC [125, 126]. Moreover, nimbolide from the leaf of the neem tree (Azadirachta indica) is another potential natural compound having antioxidant, anti-inflammatory, antibacterial, antiviral, and anticancer properties [127]. In vitro study in HCC cell line (HepG2) shows that nimbolide induces cell apoptosis by abrogating NF-κB and Wnt signaling pathway [128]. Currently, our lab is focusing on anticancer effects of nimbolide and its molecular mechanisms in an experimental hepatocarcinogenesis. Of note, these natural compounds have a wide variety of biological activities on gut microbiota and may preserve gut barrier integrity, microbial metabolites, TJ integrity, and mucosal immunology. Indeed, further human studies are warranted to see the effect of natural compounds on gut microbial modulation and prevention of HCC.
\nGut epithelial barrier acts as a fence for translocation of gut microbiota and its metabolite into the systemic circulation which is the major driving factor for CLD progression and HCC development [129]. Therefore, primarily targeting or restoring the gut epithelial barrier is an interesting therapeutic approach in HCC pathogenesis. Compelling evidence has shown that targeting gut microbiota (restoring eubiosis) directly or receptor-mediated pharmacological intervention using TLR4 antagonist or FXR agonist might improve epithelial barrier function [130, 131]. FXR is a BA receptor which is widely expressed throughout the gut-liver axis. Decreased BA is associated with intestinal bacterial overgrowth, increased gut permeability, and bacterial translocation in rodents [38]. FXR controls hepatic inflammation, promotes liver regeneration, and suppresses HCC formation mainly through enterokine FGF19 [132]. FXR null mice have an intestinal barrier dysfunction and high occurrence of HCC, whereas reactivation of FXR inhibited HCC through FGF15-cyp7a1 axis [133]. In this context, FXR agonist obeticholic acid (OCA) prevents gut barrier dysfunction and BT in cholestatic rats [131]. Furthermore, in CCl4-induced cirrhotic rats, OCA treatment significantly reduces BT and inhibits intestinal inflammation by restoring intestinal TJ proteins such as ZO-1 and occludin and antimicrobial peptides [134]. OCA treatment also improves hepatic inflammation and decreased portal pressure in BDL cirrhotic rats [135]. Consequently, OCA treatment may prevent HCC by limiting intestinal inflammation and improving gut barrier dysfunction in advanced liver disease.
\nIncreased TNF-α production in mesenteric lymph nodes by monocyte is the major factor responsible for increased intestinal permeability in cirrhosis and HCC [19, 136]. TNF-α decreases ZO-1 expression through NF-κB and MLCK activation [137]. TNF-α also downregulated occludin expression in Caco-2 enterocyte by targeting PI3k/Akt signaling [138]. In BDL rats, treatment with infliximab (IFX, a monoclonal antibody against TNF) significantly reduced portal pressure and attenuated inflammation [139]. Therefore modulating intestinal TJs protein with anti-TNF-α therapy may restore intestinal integrity. However, due to the immunosuppressive activity of TNF inhibitors, it may lead to systemic infection in cirrhosis patients. Hence, detailed knowledge for local inhibition is required for improvement in gut barrier dysfunction without affecting innate immune response.
\nRetinoic acid can modulate TJs proteins. In a mice model of colitis characterized by gut permeability, treatment with retinoic acid enhances barrier function by upregulating TJs proteins claudin-1, claudin-4, and ZO-1 [140]. However, the effect of retinoic acid in the preservation of intestinal integrity has not been tested in cirrhosis and HCC. Modulation of the epithelial barrier with probiotics seems to be beneficial. In this regard, Zhang et al. showed probiotics VSL#3 (combination of S. thermophilus, four Lactobacillus species, and three Bifidobacterium species) treatment restores intestinal permeability and dysbiosis and prevented HCC progression in rats [19]. Similarly, probiotics like E. coli Nissle1971 (ECN) was also shown to enhance intestinal TJs integrity by upregulating ZO-1 expression in the mouse model of DSS-induced colitis [141].
\nIn addition, treatment with red wine polyphenol promoted barrier function by significantly increasing mRNA expression of TJ proteins occludin, claudin-5, and ZO-1 in cytokine-stimulated HT-29 colon epithelial cells [142]. Resveratrol also preserves TJ barrier integrity and diminishes intestinal permeability by upregulating occludin, ZO-1, and claudin-1expression and thus abrogating intestinal inflammation and oxidative stress both in vivo and in vitro [143]. Similarly in NAFLD mice model, treatment with resveratrol enhances barrier function by increasing mRNA expression of TJ proteins ZO-1, occludin, and claudin-1 in the intestinal mucosa [144]. Curcumin also modulates intestinal barrier integrity and attenuates paracellular permeability and organization of TJs [145]. Thus, targeting TJ proteins, which maintain intact intestinal epithelia, is another area of therapeutic approach for the control of intestinal permeability in cirrhosis and HCC.
\nHCC is the end-stage liver disease, which mostly develops on the background of cirrhosis. As discussed above, the gut-liver axis plays a significant role in the progression of CLD and ultimately HCC and would be a potentially significant therapeutic target in the prevention of HCC. There have been several preclinical and human studies demonstrating an association between gut dysbiosis and HCC progression. However, from the animal studies, it is unclear whether gut microbiota initiates HCC or acts with other precipitating factors like chronic inflammation in the progression of HCC. Modulation of gut dysbiosis with prebiotics and probiotics, FMT, or preventing bacterial overgrowth with antibiotics may therefore prevent HCC. Moreover, in cirrhotic patients these interventions appeared to prevent secondary complications and improved survival. We may therefore speculate that the above interventions might prevent HCC development in high-risk cirrhotic patients. Moreover, we should consider trialing these therapies in HCC patients with unresectable tumors, which might improve survival time and secondary complications. Furthermore interventions that restore intestinal barrier integrity may prevent gut BT and may consider another line of therapy in HCC.
\nIn conclusion, there is growing evidence to suggest gut microbiota may play a significant role in the progression of CLD and thus HCC, which is likely to involve multiple pathways ranging from gut dysbiosis, endotoxemia, inflammation, loss of TJ integrity, and intestinal permeability. It is therefore suggested that the use of agents that have the potential to target microbial dysbiosis and restore intestinal epithelial barrier integrity may prevent bacterial translocation and ultimately delay HCC progression. However, whether bacterial overgrowth and/or intestinal permeability act independently or synergistically as causal pathogenic factors to influence the inflammatory milieu so closely associated with HCC progression remains unclear. Further research is therefore warranted to better understand the molecular pathways involved and guide the development of novel therapeutic interventions that can be taken to clinical trial to limit CLD/HCC progression through the targeting of dysbiosis and its effect on inflammation and intestinal permeability.
\nThe authors declare that they have no conflict of interest.
\nALT | alanine transaminase |
AMPs | antimicrobial peptides |
AST | aspartate transaminase |
BAs | bile acids |
BDL | bile duct ligation |
CCL | chemokine ligand |
CCl4 | carbon tetrachloride |
CD | cluster of differentiation |
CLD | chronic liver disease |
CTP | child-turcotte-pugh |
DCA | deoxycholic acid |
DEN | diethylnitrosamine |
DMBA | 2,4-dimethoxybenzaldehyde |
ERK | extracellular signal-regulated kinase |
FMT | fecal microbiota transplantation |
HCC | hepatocellular carcinoma |
HFD | high-fat diet |
HSCs | hepatic stellate cells |
IBD | inflammatory bowel disease |
IEC | intestinal epithelial cell |
IL | interleukin |
JNK | c-Jun N-terminal kinase |
LBP | lipopolysaccharide binding protein |
LPS | lipopolysaccharides |
MAMPs | microbe-associated molecular patterns |
MAPK | mitogen-activated protein kinase |
MELD | model for end-stage liver disease |
NAFLD | nonalcoholic fatty liver disease |
NASH | nonalcoholic steatohepatitis |
NF-κB | nuclear factor kappa-light-chain-enhancer of activated B cells |
NLRP | nucleotide-binding oligomerization domain, leucine-rich repeat- and pyrin domain-containing |
NSBB | nonselective beta-blockers |
OCA | obeticholic acid |
PRRs | pattern recognition receptor |
SCFAs | short-chain fatty acids |
STHD | steatohepatitis-inducing high-fat diet |
TB | total bilirubin |
TGR5 | takeda G-protein-coupled receptor 5 |
TLR | toll-like receptors |
TNF-α | tumor necrosis factor alpha |
TJs | tight junctions |
WHO | World Health Organization |
ZO | zonula occluden |
At IntechOpen, we not only specialize in the publication of Book Chapters as part of our Edited Volumes, but also the publication and dissemination of longer manuscripts, known as Long Form Monographs. Monographs allow Authors to focus on presenting a single subject or a specific aspect of that subject and publish their research in detail.
\n\nEven if you have an area of research that does not at first sight fit within a previously defined IntechOpen project, we can still offer support and help you in publishing your individual research. Publishing your IntechOpen book in the form of a Long Form Monograph is a viable alternative.
",metaTitle:"Publish a Whole Book",metaDescription:"At IntechOpen, we not only specialize in the publication of book chapters as part of our Edited Volumes, but also the publication and dissemination of long form manuscripts, known as monographs. Monographs allow authors to focus on presenting a single subject or a specific aspect of that subject and publish their research at length.\n\nPerhaps you have an area of research that does not fit within a previously defined IntechOpen project, but rather need help in publishing your individual research? Publishing your IntechOpen book in the form of a long form monograph is a great alternative.",metaKeywords:null,canonicalURL:"/page/publish-a-whole-book",contentRaw:'[{"type":"htmlEditorComponent","content":"MONOGRAPH - LONG FORM MANUSCRIPT
\\n\\nFORMATS
\\n\\nCOST
\\n\\n10,000 GBP Monograph - Long Form
\\n\\nThe final price includes project management, editorial and peer-review services, technical editing, language copyediting, cover design, book layout, book promotion and ISBN assignment.
\\n\\n*The price does not include Value-Added Tax (VAT). Residents of European Union countries need to add VAT based on the specific rate applied in their country of residence. Institutions and companies registered as VAT taxable entities in their own EU member state will not pay VAT by providing us with their VAT registration number. This is made possible by the EU reverse charge method.
\\n\\nOptional Services
\\n\\nIntechOpen has collaborated with Enago, through its sister brand, Ulatus, which is one of the world’s leading providers of book translation services. The services are designed to convey the essence of your work to readers from across the globe in a language they understand. Enago’s expert translators incorporate cultural nuances in translations to make the content relevant for local audiences while retaining the original meaning and style. Enago translators are equipped to handle all complex and multiple overlapping themes encompassed in a single book and their high degree of linguistic and subject expertise enables them to deliver a superior quality output.
\\n\\nIntechOpen Authors that wish to use this service will receive a 20% discount on all translation services. To find out more information or obtain a quote, please visit: https://www.enago.com/intech.
\\n\\nFUNDING
\\n\\nWe feel that financial barriers should never prevent researchers from publishing their work. Please consult our Open Access Funding page to explore funding opportunities and learn more about how you can finance your IntechOpen publication.
\\n\\nBENEFITS
\\n\\nPUBLISHING PROCESS STEPS
\\n\\nFor a complete overview of all publishing process steps and descriptions, go to How Open Access Publishing Works.
\\n\\nSEND YOUR PROPOSAL
\\n\\nIf you are interested in publishing your book with IntechOpen, please submit your book proposal by completing the Publishing Proposal Form.
\\n\\nNot sure if this is the right option for you? Please refer back to the main Publish with IntechOpen page or feel free to contact us directly at book.department@intechopen.com.
\\n"}]'},components:[{type:"htmlEditorComponent",content:'MONOGRAPH - LONG FORM MANUSCRIPT
\n\nFORMATS
\n\nCOST
\n\n10,000 GBP Monograph - Long Form
\n\nThe final price includes project management, editorial and peer-review services, technical editing, language copyediting, cover design, book layout, book promotion and ISBN assignment.
\n\n*The price does not include Value-Added Tax (VAT). Residents of European Union countries need to add VAT based on the specific rate applied in their country of residence. Institutions and companies registered as VAT taxable entities in their own EU member state will not pay VAT by providing us with their VAT registration number. This is made possible by the EU reverse charge method.
\n\nOptional Services
\n\nIntechOpen has collaborated with Enago, through its sister brand, Ulatus, which is one of the world’s leading providers of book translation services. The services are designed to convey the essence of your work to readers from across the globe in a language they understand. Enago’s expert translators incorporate cultural nuances in translations to make the content relevant for local audiences while retaining the original meaning and style. Enago translators are equipped to handle all complex and multiple overlapping themes encompassed in a single book and their high degree of linguistic and subject expertise enables them to deliver a superior quality output.
\n\nIntechOpen Authors that wish to use this service will receive a 20% discount on all translation services. To find out more information or obtain a quote, please visit: https://www.enago.com/intech.
\n\nFUNDING
\n\nWe feel that financial barriers should never prevent researchers from publishing their work. Please consult our Open Access Funding page to explore funding opportunities and learn more about how you can finance your IntechOpen publication.
\n\nBENEFITS
\n\nPUBLISHING PROCESS STEPS
\n\nFor a complete overview of all publishing process steps and descriptions, go to How Open Access Publishing Works.
\n\nSEND YOUR PROPOSAL
\n\nIf you are interested in publishing your book with IntechOpen, please submit your book proposal by completing the Publishing Proposal Form.
\n\nNot sure if this is the right option for you? Please refer back to the main Publish with IntechOpen page or feel free to contact us directly at book.department@intechopen.com.
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5698},{group:"region",caption:"Middle and South America",value:2,count:5172},{group:"region",caption:"Africa",value:3,count:1689},{group:"region",caption:"Asia",value:4,count:10243},{group:"region",caption:"Australia and Oceania",value:5,count:888},{group:"region",caption:"Europe",value:6,count:15647}],offset:12,limit:12,total:117315},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{sort:"dateendthirdsteppublish"},books:[],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:9},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:18},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:7},{group:"topic",caption:"Computer and Information Science",value:9,count:11},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:5},{group:"topic",caption:"Engineering",value:11,count:15},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:5},{group:"topic",caption:"Materials Science",value:14,count:4},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:62},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:1},{group:"topic",caption:"Neuroscience",value:18,count:1},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:6},{group:"topic",caption:"Physics",value:20,count:2},{group:"topic",caption:"Psychology",value:21,count:3},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:0,limit:12,total:null},popularBooks:{featuredBooks:[{type:"book",id:"7802",title:"Modern Slavery and Human Trafficking",subtitle:null,isOpenForSubmission:!1,hash:"587a0b7fb765f31cc98de33c6c07c2e0",slug:"modern-slavery-and-human-trafficking",bookSignature:"Jane Reeves",coverURL:"https://cdn.intechopen.com/books/images_new/7802.jpg",editors:[{id:"211328",title:"Prof.",name:"Jane",middleName:null,surname:"Reeves",slug:"jane-reeves",fullName:"Jane Reeves"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9961",title:"Data Mining",subtitle:"Methods, Applications and Systems",isOpenForSubmission:!1,hash:"ed79fb6364f2caf464079f94a0387146",slug:"data-mining-methods-applications-and-systems",bookSignature:"Derya Birant",coverURL:"https://cdn.intechopen.com/books/images_new/9961.jpg",editors:[{id:"15609",title:"Dr.",name:"Derya",middleName:null,surname:"Birant",slug:"derya-birant",fullName:"Derya Birant"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9157",title:"Neurodegenerative Diseases",subtitle:"Molecular Mechanisms and Current Therapeutic Approaches",isOpenForSubmission:!1,hash:"bc8be577966ef88735677d7e1e92ed28",slug:"neurodegenerative-diseases-molecular-mechanisms-and-current-therapeutic-approaches",bookSignature:"Nagehan Ersoy Tunalı",coverURL:"https://cdn.intechopen.com/books/images_new/9157.jpg",editors:[{id:"82778",title:"Ph.D.",name:"Nagehan",middleName:null,surname:"Ersoy Tunalı",slug:"nagehan-ersoy-tunali",fullName:"Nagehan Ersoy Tunalı"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8686",title:"Direct Torque Control Strategies of Electrical Machines",subtitle:null,isOpenForSubmission:!1,hash:"b6ad22b14db2b8450228545d3d4f6b1a",slug:"direct-torque-control-strategies-of-electrical-machines",bookSignature:"Fatma Ben Salem",coverURL:"https://cdn.intechopen.com/books/images_new/8686.jpg",editors:[{id:"295623",title:"Associate Prof.",name:"Fatma",middleName:null,surname:"Ben Salem",slug:"fatma-ben-salem",fullName:"Fatma Ben Salem"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9839",title:"Outdoor Recreation",subtitle:"Physiological and Psychological Effects on Health",isOpenForSubmission:!1,hash:"5f5a0d64267e32567daffa5b0c6a6972",slug:"outdoor-recreation-physiological-and-psychological-effects-on-health",bookSignature:"Hilde G. Nielsen",coverURL:"https://cdn.intechopen.com/books/images_new/9839.jpg",editors:[{id:"158692",title:"Ph.D.",name:"Hilde G.",middleName:null,surname:"Nielsen",slug:"hilde-g.-nielsen",fullName:"Hilde G. Nielsen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5141},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9785",title:"Endometriosis",subtitle:null,isOpenForSubmission:!1,hash:"f457ca61f29cf7e8bc191732c50bb0ce",slug:"endometriosis",bookSignature:"Courtney Marsh",coverURL:"https://cdn.intechopen.com/books/images_new/9785.jpg",editors:[{id:"255491",title:"Dr.",name:"Courtney",middleName:null,surname:"Marsh",slug:"courtney-marsh",fullName:"Courtney Marsh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9376",title:"Contemporary Developments and Perspectives in International Health Security",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"b9a00b84cd04aae458fb1d6c65795601",slug:"contemporary-developments-and-perspectives-in-international-health-security-volume-1",bookSignature:"Stanislaw P. Stawicki, Michael S. Firstenberg, Sagar C. Galwankar, Ricardo Izurieta and Thomas Papadimos",coverURL:"https://cdn.intechopen.com/books/images_new/9376.jpg",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7769",title:"Medical Isotopes",subtitle:null,isOpenForSubmission:!1,hash:"f8d3c5a6c9a42398e56b4e82264753f7",slug:"medical-isotopes",bookSignature:"Syed Ali Raza Naqvi and Muhammad Babar Imrani",coverURL:"https://cdn.intechopen.com/books/images_new/7769.jpg",editors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",slug:"syed-ali-raza-naqvi",fullName:"Syed Ali Raza Naqvi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9279",title:"Concepts, Applications and Emerging Opportunities in Industrial Engineering",subtitle:null,isOpenForSubmission:!1,hash:"9bfa87f9b627a5468b7c1e30b0eea07a",slug:"concepts-applications-and-emerging-opportunities-in-industrial-engineering",bookSignature:"Gary Moynihan",coverURL:"https://cdn.intechopen.com/books/images_new/9279.jpg",editors:[{id:"16974",title:"Dr.",name:"Gary",middleName:null,surname:"Moynihan",slug:"gary-moynihan",fullName:"Gary Moynihan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7807",title:"A Closer Look at Organizational Culture in Action",subtitle:null,isOpenForSubmission:!1,hash:"05c608b9271cc2bc711f4b28748b247b",slug:"a-closer-look-at-organizational-culture-in-action",bookSignature:"Süleyman Davut Göker",coverURL:"https://cdn.intechopen.com/books/images_new/7807.jpg",editors:[{id:"190035",title:"Associate Prof.",name:"Süleyman Davut",middleName:null,surname:"Göker",slug:"suleyman-davut-goker",fullName:"Süleyman Davut Göker"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editedByType:"Edited by",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editedByType:"Edited by",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9569",title:"Methods in Molecular Medicine",subtitle:null,isOpenForSubmission:!1,hash:"691d3f3c4ac25a8093414e9b270d2843",slug:"methods-in-molecular-medicine",bookSignature:"Yusuf Tutar",coverURL:"https://cdn.intechopen.com/books/images_new/9569.jpg",editedByType:"Edited by",editors:[{id:"158492",title:"Prof.",name:"Yusuf",middleName:null,surname:"Tutar",slug:"yusuf-tutar",fullName:"Yusuf Tutar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9839",title:"Outdoor Recreation",subtitle:"Physiological and Psychological Effects on Health",isOpenForSubmission:!1,hash:"5f5a0d64267e32567daffa5b0c6a6972",slug:"outdoor-recreation-physiological-and-psychological-effects-on-health",bookSignature:"Hilde G. Nielsen",coverURL:"https://cdn.intechopen.com/books/images_new/9839.jpg",editedByType:"Edited by",editors:[{id:"158692",title:"Ph.D.",name:"Hilde G.",middleName:null,surname:"Nielsen",slug:"hilde-g.-nielsen",fullName:"Hilde G. Nielsen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7802",title:"Modern Slavery and Human Trafficking",subtitle:null,isOpenForSubmission:!1,hash:"587a0b7fb765f31cc98de33c6c07c2e0",slug:"modern-slavery-and-human-trafficking",bookSignature:"Jane Reeves",coverURL:"https://cdn.intechopen.com/books/images_new/7802.jpg",editedByType:"Edited by",editors:[{id:"211328",title:"Prof.",name:"Jane",middleName:null,surname:"Reeves",slug:"jane-reeves",fullName:"Jane Reeves"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8063",title:"Food Security in Africa",subtitle:null,isOpenForSubmission:!1,hash:"8cbf3d662b104d19db2efc9d59249efc",slug:"food-security-in-africa",bookSignature:"Barakat Mahmoud",coverURL:"https://cdn.intechopen.com/books/images_new/8063.jpg",editedByType:"Edited by",editors:[{id:"92016",title:"Dr.",name:"Barakat",middleName:null,surname:"Mahmoud",slug:"barakat-mahmoud",fullName:"Barakat Mahmoud"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10118",title:"Plant Stress Physiology",subtitle:null,isOpenForSubmission:!1,hash:"c68b09d2d2634fc719ae3b9a64a27839",slug:"plant-stress-physiology",bookSignature:"Akbar Hossain",coverURL:"https://cdn.intechopen.com/books/images_new/10118.jpg",editedByType:"Edited by",editors:[{id:"280755",title:"Dr.",name:"Akbar",middleName:null,surname:"Hossain",slug:"akbar-hossain",fullName:"Akbar Hossain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9157",title:"Neurodegenerative Diseases",subtitle:"Molecular Mechanisms and Current Therapeutic Approaches",isOpenForSubmission:!1,hash:"bc8be577966ef88735677d7e1e92ed28",slug:"neurodegenerative-diseases-molecular-mechanisms-and-current-therapeutic-approaches",bookSignature:"Nagehan Ersoy Tunalı",coverURL:"https://cdn.intechopen.com/books/images_new/9157.jpg",editedByType:"Edited by",editors:[{id:"82778",title:"Ph.D.",name:"Nagehan",middleName:null,surname:"Ersoy Tunalı",slug:"nagehan-ersoy-tunali",fullName:"Nagehan Ersoy Tunalı"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9961",title:"Data Mining",subtitle:"Methods, Applications and Systems",isOpenForSubmission:!1,hash:"ed79fb6364f2caf464079f94a0387146",slug:"data-mining-methods-applications-and-systems",bookSignature:"Derya Birant",coverURL:"https://cdn.intechopen.com/books/images_new/9961.jpg",editedByType:"Edited by",editors:[{id:"15609",title:"Dr.",name:"Derya",middleName:null,surname:"Birant",slug:"derya-birant",fullName:"Derya Birant"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8686",title:"Direct Torque Control Strategies of Electrical Machines",subtitle:null,isOpenForSubmission:!1,hash:"b6ad22b14db2b8450228545d3d4f6b1a",slug:"direct-torque-control-strategies-of-electrical-machines",bookSignature:"Fatma Ben Salem",coverURL:"https://cdn.intechopen.com/books/images_new/8686.jpg",editedByType:"Edited by",editors:[{id:"295623",title:"Associate Prof.",name:"Fatma",middleName:null,surname:"Ben Salem",slug:"fatma-ben-salem",fullName:"Fatma Ben Salem"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"1056",title:"Neurology",slug:"neurology",parent:{title:"Mental and Behavioural Disorders and Diseases of the Nervous System",slug:"mental-and-behavioural-disorders-and-diseases-of-the-nervous-system"},numberOfBooks:55,numberOfAuthorsAndEditors:1700,numberOfWosCitations:634,numberOfCrossrefCitations:353,numberOfDimensionsCitations:876,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"neurology",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"9778",title:"Migraine",subtitle:null,isOpenForSubmission:!1,hash:"ba52761e098431d3113b538e9f6427f6",slug:"migraine",bookSignature:"Wojciech Kozubski",coverURL:"https://cdn.intechopen.com/books/images_new/9778.jpg",editedByType:"Edited by",editors:[{id:"83372",title:"Prof.",name:"Wojciech",middleName:null,surname:"Kozubski",slug:"wojciech-kozubski",fullName:"Wojciech Kozubski"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8087",title:"Neuroprotection",subtitle:"New Approaches and Prospects",isOpenForSubmission:!1,hash:"10acd587ca2c942616bfc09c4b79df39",slug:"neuroprotection-new-approaches-and-prospects",bookSignature:"Matilde Otero-Losada, Francisco Capani and Santiago Perez Lloret",coverURL:"https://cdn.intechopen.com/books/images_new/8087.jpg",editedByType:"Edited by",editors:[{id:"193560",title:"Dr.",name:"Matilde",middleName:null,surname:"Otero-Losada",slug:"matilde-otero-losada",fullName:"Matilde Otero-Losada"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8172",title:"Amyotrophic Lateral Sclerosis",subtitle:"Recent Advances and Therapeutic Challenges",isOpenForSubmission:!1,hash:"454a2d1c81a4a4452f791a8b31b427dd",slug:"amyotrophic-lateral-sclerosis-recent-advances-and-therapeutic-challenges",bookSignature:"Muralidhar L. Hegde",coverURL:"https://cdn.intechopen.com/books/images_new/8172.jpg",editedByType:"Edited by",editors:[{id:"264616",title:"Dr.",name:"Muralidhar L.",middleName:null,surname:"Hegde",slug:"muralidhar-l.-hegde",fullName:"Muralidhar L. Hegde"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8203",title:"Peripheral Nerve Disorders and Treatment",subtitle:null,isOpenForSubmission:!1,hash:"faa3d9b75498d42c252aa550b9346922",slug:"peripheral-nerve-disorders-and-treatment",bookSignature:"Hande Turker, Leonel Garcia Benavides, Guillermo Ramos Gallardo and Miriam Méndez Del Villar",coverURL:"https://cdn.intechopen.com/books/images_new/8203.jpg",editedByType:"Edited by",editors:[{id:"63331",title:"Prof.",name:"Hande",middleName:null,surname:"Turker",slug:"hande-turker",fullName:"Hande Turker"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7070",title:"Novel Aspects on Motor Neuron Disease",subtitle:null,isOpenForSubmission:!1,hash:"3ea8aa08fd9d45d806411a8c60b7adab",slug:"novel-aspects-on-motor-neuron-disease",bookSignature:"Humberto Foyaca Sibat and Lourdes de Fátima Ibañez-Valdés",coverURL:"https://cdn.intechopen.com/books/images_new/7070.jpg",editedByType:"Edited by",editors:[{id:"142346",title:"Prof.",name:"Humberto",middleName:null,surname:"Foyaca Sibat",slug:"humberto-foyaca-sibat",fullName:"Humberto Foyaca Sibat"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9364",title:"New Insight into Cerebrovascular Diseases",subtitle:"An Updated Comprehensive Review",isOpenForSubmission:!1,hash:"bb9cf94a9674571e55f6e01a20ec372a",slug:"new-insight-into-cerebrovascular-diseases-an-updated-comprehensive-review",bookSignature:"Patricia Bozzetto Ambrosi, Rufai Ahmad, Auwal Abdullahi and Amit Agrawal",coverURL:"https://cdn.intechopen.com/books/images_new/9364.jpg",editedByType:"Edited by",editors:[{id:"221787",title:"Dr.",name:"Patricia",middleName:null,surname:"Bozzetto Ambrosi",slug:"patricia-bozzetto-ambrosi",fullName:"Patricia Bozzetto Ambrosi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8296",title:"Multiple Sclerosis",subtitle:null,isOpenForSubmission:!1,hash:"ec14c3341208a441acbc52bc4b632c0c",slug:"multiple-sclerosis",bookSignature:"Stavros J. Baloyannis",coverURL:"https://cdn.intechopen.com/books/images_new/8296.jpg",editedByType:"Edited by",editors:[{id:"156098",title:"Emeritus Prof.",name:"Stavros",middleName:"J",surname:"Baloyannis",slug:"stavros-baloyannis",fullName:"Stavros Baloyannis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8430",title:"Neurodevelopment and Neurodevelopmental Disorder",subtitle:null,isOpenForSubmission:!1,hash:"696c96d038de473216e48b199613c111",slug:"neurodevelopment-and-neurodevelopmental-disorder",bookSignature:"Michael Fitzgerald",coverURL:"https://cdn.intechopen.com/books/images_new/8430.jpg",editedByType:"Edited by",editors:[{id:"205005",title:"Dr.",name:"Michael",middleName:null,surname:"Fitzgerald",slug:"michael-fitzgerald",fullName:"Michael Fitzgerald"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7860",title:"Epilepsy",subtitle:"Advances in Diagnosis and Therapy",isOpenForSubmission:!1,hash:"17e914e07088c3e9c4d085a609be1f42",slug:"epilepsy-advances-in-diagnosis-and-therapy",bookSignature:"Isam Jaber Al-Zwaini and Ban Adbul-Hameed Majeed Albadri",coverURL:"https://cdn.intechopen.com/books/images_new/7860.jpg",editedByType:"Edited by",editors:[{id:"30993",title:"Prof.",name:"Isam Jaber",middleName:null,surname:"Al-Zwaini",slug:"isam-jaber-al-zwaini",fullName:"Isam Jaber Al-Zwaini"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6677",title:"Recent Advances in Neurodegeneration",subtitle:null,isOpenForSubmission:!1,hash:"65c05412d2a2f134e3eaa811c921273e",slug:"recent-advances-in-neurodegeneration",bookSignature:"Antonella Borreca",coverURL:"https://cdn.intechopen.com/books/images_new/6677.jpg",editedByType:"Edited by",editors:[{id:"192832",title:"Dr.",name:"Antonella",middleName:null,surname:"Borreca",slug:"antonella-borreca",fullName:"Antonella Borreca"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7862",title:"Traumatic Brain Injury",subtitle:"Neurobiology, Diagnosis and Treatment",isOpenForSubmission:!1,hash:"247618f9fcfd8e9054e1202968e3387b",slug:"traumatic-brain-injury-neurobiology-diagnosis-and-treatment",bookSignature:"Yongxia Zhou",coverURL:"https://cdn.intechopen.com/books/images_new/7862.jpg",editedByType:"Edited by",editors:[{id:"259308",title:"Dr.",name:"Yongxia",middleName:null,surname:"Zhou",slug:"yongxia-zhou",fullName:"Yongxia Zhou"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7581",title:"Neuroprotection",subtitle:null,isOpenForSubmission:!1,hash:"0a01b892051ad12c316ddf17801b962e",slug:"neuroprotection",bookSignature:"Raymond Chuen-Chung Chang and Yuen-Shan Ho",coverURL:"https://cdn.intechopen.com/books/images_new/7581.jpg",editedByType:"Edited by",editors:[{id:"33396",title:"Dr.",name:"Raymond Chuen-Chung",middleName:null,surname:"Chang",slug:"raymond-chuen-chung-chang",fullName:"Raymond Chuen-Chung Chang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:55,mostCitedChapters:[{id:"24857",doi:"10.5772/28930",title:"Hormonal Signaling Systems of the Brain in Diabetes Mellitus",slug:"hormonal-signaling-systems-of-the-brain-in-diabetes-mellitus",totalDownloads:1673,totalCrossrefCites:3,totalDimensionsCites:24,book:{slug:"neurodegenerative-diseases-processes-prevention-protection-and-monitoring",title:"Neurodegenerative Diseases",fullTitle:"Neurodegenerative Diseases - Processes, Prevention, Protection and Monitoring"},signatures:"Alexander Shpakov, Oksana Chistyakova, Kira Derkach and Vera Bondareva",authors:[{id:"75886",title:"Dr",name:"Vera",middleName:null,surname:"Bondareva",slug:"vera-bondareva",fullName:"Vera Bondareva"},{id:"75888",title:"Prof.",name:"Alexander",middleName:null,surname:"Shpakov",slug:"alexander-shpakov",fullName:"Alexander Shpakov"},{id:"81684",title:"Dr",name:"Oksana",middleName:null,surname:"Chistyakova",slug:"oksana-chistyakova",fullName:"Oksana Chistyakova"},{id:"81685",title:"Dr.",name:"Kira",middleName:null,surname:"Derkach",slug:"kira-derkach",fullName:"Kira Derkach"}]},{id:"51342",doi:"10.5772/63824",title:"Autoimmune Processes in Multiple Sclerosis: Production of Harmful Catalytic Antibodies Associated with Significant Changes in the Hematopoietic Stem Cell Differentiation and Proliferation",slug:"autoimmune-processes-in-multiple-sclerosis-production-of-harmful-catalytic-antibodies-associated-wit",totalDownloads:754,totalCrossrefCites:5,totalDimensionsCites:21,book:{slug:"trending-topics-in-multiple-sclerosis",title:"Trending Topics in Multiple Sclerosis",fullTitle:"Trending Topics in Multiple Sclerosis"},signatures:"Georgy A. Nevinsky",authors:[{id:"47119",title:"Dr.",name:"Georgy",middleName:null,surname:"Nevinsky",slug:"georgy-nevinsky",fullName:"Georgy Nevinsky"}]},{id:"44546",doi:"10.5772/54305",title:"Astrocytes Role in Parkinson: A Double-Edged Sword",slug:"astrocytes-role-in-parkinson-a-double-edged-sword",totalDownloads:3892,totalCrossrefCites:9,totalDimensionsCites:14,book:{slug:"neurodegenerative-diseases",title:"Neurodegenerative Diseases",fullTitle:"Neurodegenerative Diseases"},signatures:"Ricardo Cabezas, Marco Fidel Avila, Daniel Torrente, Ramon Santos\nEl-Bachá, Ludis Morales, Janneth Gonzalez and George E. Barreto",authors:[{id:"85869",title:"Prof.",name:"George",middleName:"E.",surname:"Barreto",slug:"george-barreto",fullName:"George Barreto"},{id:"88549",title:"Dr.",name:"Ludis",middleName:null,surname:"Morales",slug:"ludis-morales",fullName:"Ludis Morales"},{id:"97601",title:"Dr.",name:"Janneth",middleName:null,surname:"Gonzalez",slug:"janneth-gonzalez",fullName:"Janneth Gonzalez"},{id:"157020",title:"MSc.",name:"Ricardo",middleName:null,surname:"Cabezas",slug:"ricardo-cabezas",fullName:"Ricardo Cabezas"},{id:"157021",title:"MSc.",name:"Marco Fidel",middleName:null,surname:"Ávila",slug:"marco-fidel-avila",fullName:"Marco Fidel Ávila"},{id:"165566",title:"Dr.",name:"Ramon",middleName:null,surname:"El-Bachá",slug:"ramon-el-bacha",fullName:"Ramon El-Bachá"},{id:"167253",title:"Mr.",name:"Daniel",middleName:null,surname:"Torrente",slug:"daniel-torrente",fullName:"Daniel Torrente"}]}],mostDownloadedChaptersLast30Days:[{id:"60608",title:"Mucuna and Parkinson’s Disease: Treatment with Natural Levodopa",slug:"mucuna-and-parkinson-s-disease-treatment-with-natural-levodopa",totalDownloads:3197,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"parkinson-s-disease-understanding-pathophysiology-and-developing-therapeutic-strategies",title:"Parkinson's Disease",fullTitle:"Parkinson's Disease - Understanding Pathophysiology and Developing Therapeutic Strategies"},signatures:"Rafael González Maldonado",authors:[{id:"214658",title:"Dr.",name:"Rafael",middleName:null,surname:"Gonzalez-Maldonado",slug:"rafael-gonzalez-maldonado",fullName:"Rafael Gonzalez-Maldonado"}]},{id:"73869",title:"Neuroactive Steroids in Hypoxic–Ischemic Brain Injury: Overview and Future Directions",slug:"neuroactive-steroids-in-hypoxic-ischemic-brain-injury-overview-and-future-directions",totalDownloads:153,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"neuroprotection-new-approaches-and-prospects",title:"Neuroprotection",fullTitle:"Neuroprotection - New Approaches and Prospects"},signatures:"Nicolas Toro-Urrego, Marco Avila-Rodriguez, María Inés Herrera, Andrea Aguilar, Lucas Udovin and Juan P. Luaces",authors:[{id:"306021",title:"Dr.",name:"Lucas",middleName:null,surname:"Udovin",slug:"lucas-udovin",fullName:"Lucas Udovin"},{id:"306022",title:"Dr.",name:"María Inés",middleName:null,surname:"Herrera",slug:"maria-ines-herrera",fullName:"María Inés Herrera"},{id:"308465",title:"Dr.",name:"Nicolás",middleName:null,surname:"Toro Urrego",slug:"nicolas-toro-urrego",fullName:"Nicolás Toro Urrego"},{id:"308469",title:"Dr.",name:"Juan P.",middleName:null,surname:"Luaces",slug:"juan-p.-luaces",fullName:"Juan P. Luaces"},{id:"311483",title:"Dr.",name:"Marco Fidel",middleName:null,surname:"Avila-Rodriguez",slug:"marco-fidel-avila-rodriguez",fullName:"Marco Fidel Avila-Rodriguez"},{id:"332900",title:"Dr.",name:"Andrea",middleName:null,surname:"Aguilar",slug:"andrea-aguilar",fullName:"Andrea Aguilar"}]},{id:"54350",title:"Trichodynia (Scalp Dysesthesia)",slug:"trichodynia-scalp-dysesthesia-",totalDownloads:2789,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"current-perspectives-on-less-known-aspects-of-headache",title:"Current Perspectives on Less-known Aspects of Headache",fullTitle:"Current Perspectives on Less-known Aspects of Headache"},signatures:"Müge Güler Özden",authors:[{id:"63332",title:"Dr.",name:"Müge",middleName:null,surname:"Güler Özden",slug:"muge-guler-ozden",fullName:"Müge Güler Özden"}]},{id:"25209",title:"Frontotemporal Lobar Degeneration",slug:"frontotemporal-lobar-degeneration",totalDownloads:2497,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"advanced-understanding-of-neurodegenerative-diseases",title:"Advanced Understanding of Neurodegenerative Diseases",fullTitle:"Advanced Understanding of Neurodegenerative Diseases"},signatures:"Johannes Schlachetzki",authors:[{id:"72961",title:"Dr.",name:"Johannes",middleName:null,surname:"Schlachetzki",slug:"johannes-schlachetzki",fullName:"Johannes Schlachetzki"}]},{id:"58504",title:"Management of Intracranial Pressure in Traumatic Brain Injury",slug:"management-of-intracranial-pressure-in-traumatic-brain-injury",totalDownloads:1106,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"traumatic-brain-injury-pathobiology-advanced-diagnostics-and-acute-management",title:"Traumatic Brain Injury",fullTitle:"Traumatic Brain Injury - Pathobiology, Advanced Diagnostics and Acute Management"},signatures:"Christ Ordookhanian, Meena Nagappan, Dina Elias and Paul E.\nKaloostian",authors:[{id:"209339",title:"Dr.",name:"Paul",middleName:null,surname:"Kaloostian",slug:"paul-kaloostian",fullName:"Paul Kaloostian"}]},{id:"56812",title:"Targeted Temperature Management in Traumatic Brain Injury",slug:"targeted-temperature-management-in-traumatic-brain-injury",totalDownloads:787,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"traumatic-brain-injury-pathobiology-advanced-diagnostics-and-acute-management",title:"Traumatic Brain Injury",fullTitle:"Traumatic Brain Injury - Pathobiology, Advanced Diagnostics and Acute Management"},signatures:"Sombat Muengtaweepongsa and Pornchai Yodwisithsak",authors:[{id:"64867",title:"Dr.",name:"Sombat",middleName:null,surname:"Muengtaweepongsa",slug:"sombat-muengtaweepongsa",fullName:"Sombat Muengtaweepongsa"}]},{id:"51622",title:"Assessments and Outcome Measures of Cerebral Palsy",slug:"assessments-and-outcome-measures-of-cerebral-palsy",totalDownloads:3708,totalCrossrefCites:3,totalDimensionsCites:3,book:{slug:"cerebral-palsy-current-steps",title:"Cerebral Palsy",fullTitle:"Cerebral Palsy - Current Steps"},signatures:"Ayşe Numanoğlu Akbaş",authors:[{id:"181610",title:"Dr.",name:"Ayşe",middleName:null,surname:"Numanoğlu Akbaş",slug:"ayse-numanoglu-akbas",fullName:"Ayşe Numanoğlu Akbaş"}]},{id:"57622",title:"Age-Dependent Responses Following Traumatic Brain Injury",slug:"age-dependent-responses-following-traumatic-brain-injury",totalDownloads:779,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"traumatic-brain-injury-pathobiology-advanced-diagnostics-and-acute-management",title:"Traumatic Brain Injury",fullTitle:"Traumatic Brain Injury - Pathobiology, Advanced Diagnostics and Acute Management"},signatures:"Thomas Brickler, Paul Morton, Amanda Hazy and Michelle H. Theus",authors:[{id:"209386",title:"Dr.",name:"Michelle",middleName:null,surname:"Theus",slug:"michelle-theus",fullName:"Michelle Theus"},{id:"209387",title:"Dr.",name:"Thomas",middleName:null,surname:"Brickler",slug:"thomas-brickler",fullName:"Thomas Brickler"},{id:"221914",title:"Dr.",name:"Paul",middleName:null,surname:"Morton",slug:"paul-morton",fullName:"Paul Morton"},{id:"221915",title:"Ms.",name:"Amanda",middleName:null,surname:"Hazy",slug:"amanda-hazy",fullName:"Amanda Hazy"}]},{id:"51054",title:"The Role of Nurses in Parkinson's Disease",slug:"the-role-of-nurses-in-parkinson-s-disease",totalDownloads:4427,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"challenges-in-parkinson-s-disease",title:"Challenges in Parkinson's Disease",fullTitle:"Challenges in Parkinson's Disease"},signatures:"Michelle Hyczy de Siqueira Tosin and Beatriz Guitton Renaud\nBaptista de Oliveira",authors:[{id:"181642",title:"Dr.",name:"Michelle",middleName:"Hyczy De Siqueira",surname:"Tosin",slug:"michelle-tosin",fullName:"Michelle Tosin"},{id:"182956",title:"Prof.",name:"Beatriz",middleName:null,surname:"Oliveira",slug:"beatriz-oliveira",fullName:"Beatriz Oliveira"}]},{id:"41711",title:"Cognitive Behavioral Therapy Approach for Suicidal Thinking and Behaviors in Depression",slug:"cognitive-behavioral-therapy-approach-for-suicidal-thinking-and-behaviors-in-depression",totalDownloads:6671,totalCrossrefCites:2,totalDimensionsCites:3,book:{slug:"mental-disorders-theoretical-and-empirical-perspectives",title:"Mental Disorders",fullTitle:"Mental Disorders - Theoretical and Empirical Perspectives"},signatures:"John D. Matthews",authors:[{id:"87736",title:"Dr.",name:"John",middleName:null,surname:"Matthews",slug:"john-matthews",fullName:"John Matthews"}]}],onlineFirstChaptersFilter:{topicSlug:"neurology",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/116974/yi-heng-li",hash:"",query:{},params:{id:"116974",slug:"yi-heng-li"},fullPath:"/profiles/116974/yi-heng-li",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()